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Abstract 
Over the past decade, our understanding of the role of stress in serious mental illness has 
become more sophisticated. In this paper, we revisit the neural diathesis-stress model of 
schizophrenia that was initially proposed in 1997 and updated in 2008. In light of cumulative 
research findings, we must now encompass evidence on the premorbid periods of psychosis, 
and our more nuanced understanding of hypothalamic-pituitary-adrenal (HPA) axis function 
and its association with neurodevelopmental, epigenetic, neurotransmitter, and inflammatory 
processes, as well as brain structure and function. Giving consideration to the methodological 
complexities that have become more apparent as research in this area has burgeoned, the 
various indices of HPA axis function, and the different stages of illness, we review relevant 
research published since the 2008 update of the model. We conclude by proposing an extended 
neural diathesis-stress model that addresses the broader neurobiological context of stress 
psychobiology in psychosis progression. Implications of this model for best practice, with 
regards to both future research and treatment strategies, are discussed. 
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1. Introduction 
Stress has long been implicated in the etiology of mental illness, yet it is only within the past 
two decades that the neurobiological processes mediating this effect have been elucidated by 
basic and clinical research. In the case of psychotic disorders, which are among the most 
debilitating mental illnesses, theorists postulated a role for stress in the 1960s (Rosenthal, 
1966), but it was not until the 1990’s that specific neurobiological mediators were proposed. In 
1997, the “neural diathesis stress” model of psychosis was proposed, a model that focused on 
the role of the hypothalamic-pituitary-adrenal (HPA) axis in triggering and exacerbating 
psychotic symptoms (Walker and Diforio, 1997). The model was later updated to incorporate 
subsequent empirical findings that were consistent with its predictions (Walker et al., 2008). 
Since the publication of the updated neural diathesis stress model in 2008, research on stress 
neurobiology, including the role of stress and the HPA axis in mental disorders, has burgeoned. 
In the present paper, we review the findings from studies of HPA axis abnormalities in 
diagnosed patients with established and first episode psychosis (FEP), as well as individuals at 
clinical high risk (CHR) and genetic high risk (GHR) for psychosis, to which the authors of this 
review have made significant contributions. We consider results obtained with various research 
designs and methodological approaches, contemplate caveats and challenges in stress 
research, and take into account the multiple mechanisms that appear to act in concert with the 
HPA axis in setting the stage for psychosis. We conclude by offering an updated model that 
considers the complex interplay of vulnerability factors, neurobiological processes and 
psychosis progression. Finally, we suggest avenues for future research that might help to 
overcome and understand inconsistencies in this field, and discuss the implications of these 
findings for treatment options.  
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1.1 Stress and the HPA Axis 
As typically conceptualized by researchers, stress entails a threat to the organism’s homeostasis 
(Frodl and O'Keane, 2013, Hostinar et al., 2014). Broadly defined, the events or ‘stressors’ that 
precipitate a sense of threat can be psychological (e g., social rejection) or biological (e g., 
physical injury or illness). With respect to the former, the nature of the events that are 
construed as stressors by humans varies among individuals as a function of their personal 
histories, personality traits, and cognitive appraisals. Thus a relatively benign rebuff by a 
stranger might be construed as a threat and elicit a biological stress response in some 
individuals, but not others.  
Multiple neurobiological systems are activated by stress exposure, and chief among them are 
the sympatho-adrenal medullary system (SAM) and HPA axis (Joels and Baram, 2009). Both 
systems govern the release of secretagogues (neurotransmitters, enzymes and hormones) that 
have the potential to alter brain function. The SAM is activated first and is generally assumed to 
have more short-term effects when compared to the HPA axis. Further, it is the HPA axis that 
has received the greatest attention from researchers in the field of psychopathology, and thus 
it will be the main focus here.  
A detailed review of the literature on HPA axis structure and function is beyond the scope of 
this paper, so the reader is referred to recent overviews that integrate findings from animal and 
human research (Joels and Baram, 2009, Hostinar et al., 2014). Instead, we describe here the 
general mechanisms of HPA activity and the impact of its hormonal cascade. Later in this paper 
we examine in greater detail the association of HPA axis activation with neuronal structure and 
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function and its role in neuroinflammatory, neurodevelopmental, and epigenetic processes, as 
well as modulation of dopamine (DA) activity. 
The sensory processing of stressful stimuli results in the release of corticotrophin releasing 
hormone (CRH) from the periventricular nucleus of the hypothalamus. This, in turn, stimulates 
the anterior pituitary to secrete adrenocorticotropin releasing hormone (ACTH), which then 
serves to trigger the secretion of glucocorticoids (corticosterone in rodents and cortisol in 
primates) by the adrenals. Cortisol is the most frequently reported HPA axis measure in 
research and clinical settings, as it can be easily assayed in blood, urine and saliva. Cortisol 
assessment in saliva has become the method of choice in the majority of recent studies, as it 
constitutes a practical and non-invasive tool to reliably measure HPA axis function. 
Consequently, the focus of our review on HPA axis function will be on cortisol findings. 
There are receptors for glucocorticoids throughout the brain, and activation of these serves to 
provide negative feedback to the hypothalamus to modulate subsequent release of 
glucocorticoids. Recent evidence from animal research indicates that the negative feedback 
mechanism involves a complex neurochemical signaling process, such that glucocorticoid 
receptor activation of hypothalamic neurons following stress serves to dampen the release of 
CRH via GABA synapses that undergo a change in activity (Inoue et al., 2013). Because the 
feedback system that keeps HPA activation within normal limits is dependent on the 
functioning of glucocorticoid receptors, the distribution and sensitivity of these receptors is of 
critical importance in adaptation to stress. 
As a biological system, the HPA axis is essential for survival because it enables the organism to 
prepare for threatening events and to adjust its behavior to regain homeostasis after stress 
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exposure. Yet, it is also evident that prolonged activation of the HPA axis, with persistent 
hypersecretion of glucocorticoids, can have adverse effects on brain structure/function and 
behavior (McEwen and Gianaros, 2010, Pruessner et al., 2010). These adverse effects involve 
changes in regional brain volumes as well as changes in neuronal structure and function. Some 
of the neurobiological pathways leading from stress to brain dysfunction and recent evidence 
concerning their potential role in psychosis are described in greater detail below. 
It is also important to note that there are developmental changes in HPA function. In particular, 
there are pronounced normative increases in cortisol secretion with the transition into 
adolescence (Shirtcliff et al., 2012, Holtzman et al., 2013). Further, in healthy subjects, basal 
cortisol secretion continues to increase with age through adolescence and young adulthood 
(Walker et al., 2013a). Thus HPA axis function is influenced not only by exogenous stressors, but 
also by endogenous developmental processes. Moreover, the developmental period associated 
with normative increases in cortisol secretion is also the period linked with increased risk for 
onset of mood and psychotic disorders. 
 
1.2 Stress and Psychosis: Initial Evidence Concerning the HPA Axis 
Before exploring recent developments in our scientific understanding of the role of the stress 
and the HPA axis in psychosis, the key research findings that served as the framework for the 
previous conceptualizations of the neural diathesis-stress model will be summarized (Walker 
and Diforio, 1997, Walker et al., 2008). The model drew on the accumulated scientific evidence 
that the HPA axis was activated in response to stress exposure and that its’ secretagogues, 
especially the glucocorticoids, could have widespread effects on brain structure and function. 
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Glucocorticoids had been shown to alter neuronal functioning and augment the activity of 
neurotransmitter systems and circuits that had been implicated in the pathophysiology of 
psychosis. In particular, augmentation of the neurotransmitter DA, which has dominated 
theorizing about the pathophysiology of psychosis for decades, had been shown to be 
enhanced by glucocorticoid secretion. 
As described by Walker et al. (Walker et al., 2008), there were eight lines of investigation that 
yielded findings consistent with the model: 1) when compared to healthy controls, indices of 
basal/baseline HPA activity (cortisol and adrenocorticotropic hormone) are elevated in patients 
with schizophrenia and other psychoses, especially in non-medicated and first-episode patients; 
2) antipsychotic medications typically reduce cortisol, with more pronounced reductions in drug 
responders; 3) both prescription and recreational drugs that exacerbate or induce psychotic 
symptoms also increase HPA activity; 4) illnesses (e.g., Cushing syndrome) associated with 
increased cortisol secretion are also linked with heightened risk for psychotic 
symptoms/syndromes; 5) receptors for glucocorticoids appear to be down regulated in 
psychotic patients, suggesting reduced negative feedback on the HPA axis; 6) reduced 
hippocampal volume, a correlate of hypercortisolemia, is among the most consistently reported 
brain abnormalities in psychotic patients; 7) in humans, there is a normative increase in 
baseline cortisol secretion and HPA reactivity during the course of adolescence/young 
adulthood - the same developmental period when risk for psychosis-onset rises; and 8) the 
increase in cortisol secretion appears to precede and predict the onset of clinical psychosis in 
at-risk individuals. 
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2. Complexities and Caveats in Stress Research 
Of course, research with humans, especially clinical populations, often involves confounds that 
can obscure findings and complicate their interpretation. Before turning to our review of the 
recent literature on stress and psychosis, several methodological issues that bear on the 
interpretation of often inconsistent findings should be noted. These include challenges in the 
measurement of stress and symptoms, the effects of study design, psychotropic medications, 
sex differences and sociodemographic factors, and differences in cortisol measures and their 
implications. Although a detailed discussion of these methodological issues is beyond the scope 
of this paper, it is useful to acknowledge these issues before discussing recent findings, so they 
can be taken into consideration when drawing inferences based on the research trends. 
 
2.1 The Nature of Stressful Events  
A first measurement caveat to note is that conventional self-report measures of life course and 
everyday stress include events that are assumed to be subjectively stressful to most individuals 
(e.g., accidents, financial losses, social losses). However, it is clear that subjective experiences 
of stress are idiosyncratic: events that are deemed stressful by healthy individuals may not be 
salient to those suffering from or at risk of mental illness. Furthermore, when considering stress 
in relation to psychotic disorders, our conceptualization must encompass the stress related to 
preclinical symptoms, the illness itself, perceived stigma, and changes in social relationships 
and functioning. For example, hallucinations and delusions, as well as the attenuated positive 
symptoms that emerge in the prodrome, have the potential to trigger stress responses that are 
not tied to external events (Ward et al., 2014). These stress responses may equal or exceed 
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those triggered by actual events, yet they would not be indexed by conventional measures of 
life event or daily stress exposure.  
 
2.2 The associations among different stress measures 
A second issue concerns the poor correspondence between various measures of stress. For 
example, self-reported levels of stress and physiological markers of stress have been shown to 
be significantly related in only 25% of studies, which could be based on physiological or 
methodological particularities, or just reflect differences in motivational engagement and social 
desirability (Campbell and Ehlert, 2012). Furthermore, preexisting levels of chronic life stress 
and other psychosocial factors can affect biological stress responses (e g., heart rate and blood 
pressure) to acute stress (Chida and Hamer, 2008), and physiological stress responses of the 
HPA axis and the SAM might be opposite, actually reflecting compensatory mechanisms 
(Andrews et al., 2012, Andrews and Pruessner, 2013).  
 
2.3 Limited range in positive symptom severity 
A third methodological issue to consider is the limited variance in established symptom 
domains, which can lead to misleading conclusions when assessing their relationship with stress 
and biomarkers. For example, the commonly used Structured Interview for Prodromal 
Syndromes (SIPS) (Woods et al., 2009) and the Comprehensive Assessment of At‐Risk Mental 
States (CAARMS) (Yung et al., 2005) have upper and lower severity score thresholds for 
designating risk status. While designation as “prodromal” requires that the individual manifest 
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a score of 3 to 5 on the six point severity rating scale on at least one of the attenuated positive 
symptoms on the SIPS, individuals with scores at the lower or upper end of the scale are 
typically excluded from the sample, because they do not meet criteria for high risk (score 1 or 
2), or their symptoms have already reached psychotic severity (score 6). Such exclusion criteria 
are not applied to ratings of the negative or mood (e g., depression, anxiety) symptoms. As a 
result, studies using the SIPS and similar measures yield clinical at-risk samples that manifest a 
restricted range of scores on the positive symptom ratings, but not the other symptom 
domains. Similarly, by definition, diagnostic criteria for psychotic disorders have no exclusion 
based on the upper end of the severity distribution of positive symptoms, but in order to meet 
diagnostic criteria, the lower end must exceed a minimum level of severity. In the context of 
research, there may also be constraints at the upper end of the continuum of symptom severity 
in that patients who are acutely psychotic or manifest severe negative symptoms that impede 
engagement are very unlikely to be recruited to a research study. This will, of course, reduce 
the likelihood that ratings of positive symptoms will correlate with other measures in both 
psychotic and CHR samples.  
 
2.4 Cross-Sectional versus Repeated Measures Approaches 
Study design is a fourth consideration in the interpretation of data on stress and psychotic 
syndromes and symptoms. In particular, there are significant limitations to cross-sectional 
studies in their ability to detect reliable relations of stress measures with symptoms and illness 
course (Holtzman et al., 2013). With respect to cortisol, the neurobiological effects of 
circulating glucocorticoids on brain function and behavior are determined by multiple 
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endogenous factors, most notably glucocorticoid (GR) and mineralocorticoid (MR) receptor 
distributional patterns, densities and sensitivities. Thus, even if basal cortisol levels were 
invariant across individuals, the brain and behavioral effects of cortisol will vary among subjects 
due to receptor characteristics. Individual differences in receptor characteristics will also 
influence the magnitude of negative feedback on the HPA axis, and, therefore, the cortisol 
response to stress (Raison and Miller, 2003, van Rossum and Lamberts, 2004). For this reason, 
studies employing longitudinal, repeated-measures to examine the covariance between 
biomarkers and symptom severity levels hold the greatest promise for detecting causal 
relationships. Similarly, there are stable individual differences in the thresholds for reporting 
both stressful events and the subjective ratings of their stressfulness. A key determinant of the 
biobehavioral effects of an individual’s subjective distress may be the discrepancy between the 
person’s “average” distress and the increase in distress elicited by a particular event. As with 
biomarkers, the optimal approach to testing the relation of stress with symptom severity is the 
repeated measurement of both factors over time. 
 
2.5 Psychotropic Medication 
Fifth, psychotropic medications can affect baseline HPA hormones. The most common effect is 
a dampening of HPA activity documented with atypical antipsychotics (Zhang et al., 2005, Cohrs 
et al., 2006, Venkatasubramanian et al., 2010) and some antidepressants (Manthey et al., 
2011). Other antidepressants (Manthey et al., 2011) and stimulant medication (Wang et al., 
2012), however, can acutely increase cortisol secretion. Since most diagnosed patients with 
psychosis are on one or more psychotropics, and many individuals with prodromal 
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signs/syndromes also have a history of psychopharmacologic treatment (Woods et al., 2013), 
medication has the potential to obscure differences in HPA indices between clinical and healthy 
comparison groups. Because atypical antipsychotics and antidepressants usually suppress HPA 
activity, the result will often be an underestimation of differences between patient and control 
groups. 
Moreover, symptom severity is linked with both the likelihood that medication will be 
prescribed and the dosage recommended (Woods et al., 2009). Nonetheless, when significant 
correlations are observed between baseline cortisol and symptom severity, they are 
consistently positive in both psychotic (Belvederi Murri et al., 2012) and CHR patients (Walker 
et al., 2013b). Thus, it is plausible that those with the greatest pretreatment elevations in HPA 
activity are the most likely to be medicated. If prodromal symptom severity is even modestly 
linked with HPA activity prior to medication, then the medicated patients may have 
experienced a medication-induced dampening of HPA activity prior to baseline assessment. 
Again, the consequence will be an underestimation of group differences in HPA indices. 
 
2.6 Sex differences and Interactions 
A sixth caveat to be considered is the presence of sex differences. Male compared to female 
patients have higher rates of treated incidence of psychosis (Aleman et al., 2003, Anderson et 
al., 2012), show an earlier age of onset (Hafner et al., 1998, Cascio et al., 2012), exhibit more 
negative symptoms (Morgan et al., 2008, Chang et al., 2011), experience greater functional and 
social impairment (Scott, 2011), and are treated with higher doses of antipsychotic medication 
(Smith, 2010). Some of the sex differences that characterize psychotic patients have also been 
 
 
18 
observed in CHR patients (Walder et al., 2013, Barajas et al., 2015), including greater social role 
functioning impairments and (prodromal) symptom severity in male compared to female 
patients. In fact, poorer baseline social functioning and greater positive symptoms predicted 
higher conversion rates in male but not female patients (Walder et al., 2013).  
Sex differences have also been reported for various indices of HPA axis function in both animal 
and human studies (for reviews see, (Kirschbaum et al., 1999, Kudielka and Kirschbaum, 2005, 
Goel et al., 2014). In rodents, both basal and corticosterone secretion in response to physical 
and psychological stressors are consistently reported to be higher in females compared to 
males (Goel et al., 2014). In humans, the picture is less conclusive. Basal cortisol levels (Paris et 
al., 2010) and cortisol increases in response to the TSST (Kudielka and Kirschbaum, 2005) 
appear to be higher in men compared to women, whereas studies employing pharmacological 
stimulation of the HPA axis, physical stressors or tasks involving social rejection, tend to elicit 
greater cortisol responses in women (Goel et al., 2014). Studies on the cortisol awakening 
response (CAR) demonstrate a comparable cortisol increase in healthy men and women, but a 
delayed decrease to baseline levels in women (Pruessner et al., 1997a, Wust et al., 2000). 
However, a recent population-based study found no sex difference in the CAR in adolescents 
(Bouma et al., 2009). Based on these findings, the consideration of sex differences has the 
potential to explain inconclusive findings related to group differences between patients and 
healthy controls and related to associations between symptoms and stress markers. 
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2.7 Sociodemographic factors 
A final caveat to consider when evaluating the relationship between psychosis and HPA axis 
function relates to the potentially confounding effects of sociodemographic factors. Ethnic 
differences in schizophrenia/psychosis rates have been the source of much investigation in the 
UK with pooled data indicating that the risk of schizophrenia is approximately 4-5 fold higher 
among black Caribbean and black African groups relative to the white British population 
(Kirkbride et al., 2012). Although less frequently investigated, rates of schizophrenia have been 
found to be similarly elevated among African American individuals relative to Caucasian 
persons in the US (Bresnahan et al., 2007). There is additionally evidence of socioeconomic 
differences in schizophrenia/psychosis risk. Specifically, increased risk of schizophrenia has 
been associated with both low socioeconomic status in childhood (Wicks et al., 2005, Corcoran 
et al., 2009) and residing in neighborhoods of increased deprivation in adulthood (Kirkbride et 
al., 2014). 
While the mechanisms underlying the relationship of schizophrenia and other psychoses with 
ethnic minority and lower socioeconomic status are unclear, importantly, both 
sociodemographic factors have also been associated with HPA axis function. Studies in the US 
have reported that relative to Caucasian individuals, those of black ethnicity are characterized 
by higher baseline cortisol levels in the evening (Cohen et al., 2006, Fuller-Rowell et al., 2012) 
lower cortisol levels upon awakening (DeSantis et al., 2007, Fuller-Rowell et al., 2012), and a 
more blunted cortisol response during psychosocial stressor tasks (Chong et al., 2008). 
Additionally, studies of both children (Lupien et al., 2001) and adults (Cohen et al., 2006) have 
observed elevated baseline cortisol levels among individuals of low socioeconomic status 
compared to individuals from high socioeconomic backgrounds. A large study of adolescents 
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further reported a U-shaped association between socioeconomic status and CAR, such that 
adolescents from high and low socioeconomic families showed a blunted CAR relative to 
adolescents from intermediate families (Marsman et al., 2012). Thus, ethnicity and 
socioeconomic status should be considered as important factors that may confound, mediate, 
or modify the relationship between HPA axis function and psychosis. 
 
 
2.8. The measurement of baseline cortisol and cortisol change 
2.8.1 Baseline cortisol measures: 
 The term ‘baseline’ has typically been used to refer to the initial measurement of a variable in 
the absence of any experimental manipulation or exposure (Rogosa, 1995). ‘Baseline’ cortisol 
levels can be estimated by obtaining a single fluid sample (saliva, urine, or blood). Because 
cortisol exhibits a distinct circadian rhythm (levels are highest in the morning, gradually 
decline throughout the day, and rise again during sleep), controlling for sampling time is 
important when employing single cortisol samples as baseline measures. To overcome this 
problem, some studies have obtained multiple samples throughout the day to examine diurnal 
patterns of secretion. These multiple measures can then be analyzed using repeated measures 
statistics or calculating the area under the curve (AUC) (Pruessner et al., 2003a), yielding a 
single value that is informative of baseline HPA axis function. A relatively novel method to 
retrospectively assess HPA axis activity over extended periods of time is hair cortisol (Beasley 
et al., 2000, Russell et al., 2012, Stalder and Kirschbaum, 2012, Staufenbiel et al., 2013). This 
method measures systemic cortisol exposure on a month by month basis, and can provide 
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useful complementary information to the real time cortisol measures captured with other 
methods.  
 
2.8.2 Cortisol levels in response to stimulation 
Repeated cortisol sampling has also been used to examine changes following exposure to (i) 
experimentally-induced stress, (ii) naturally occurring stressors, or (iii) pharmacological 
challenge. Changes in HPA axis activity in response to acute stress are typically elicited with 
psychosocial stressor tasks and usually involve assessing cortisol levels before, during, and 
after the task.  
 
2.8.2.1 The Cortisol Awakening Response (CAR) 
The cortisol awakening response (CAR) refers to the sharp increase in cortisol that typically 
occurs within 15-40 minutes of waking (Pruessner et al., 1997b). The CAR seems to be distinct 
from – and superimposed on — the diurnal cortisol course, and is thought to be triggered by 
the sleep-wake transition and the associated anticipation of the upcoming day (Wilhelm et al., 
2007, Fries et al., 2009). It is conceivable that cortisol measures taken in close proximity to the 
time of awakening are influenced by the awakening process rather than reflecting ‘baseline’ 
cortisol secretion. Due to challenges with reliably measuring the CAR, especially outside of the 
laboratory, investigators in the area have recently proposed guidelines for obtaining measures 
of the CAR and analyzing CAR data (Stalder et al., 2016). 
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2.8.2.2 The Trier Social Stress Test 
The Trier Social Stress Test (TSST) is an established laboratory protocol to evaluate cortisol and 
other physiological responses to a moderate psychosocial stressor, typically consisting of a job 
interview and mental arithmetic (5 minutes each) in front of an audience and a camera 
(Kirschbaum et al., 1993). The task aims to induce social evaluative threat and 
uncontrollability, two important characteristics of psychological stressors to evoke strong 
cortisol responses in target individuals (Dickerson and Kemeny, 2004). In order to minimize 
the impact of diurnal rhythm on the cortisol responses, all participants should be seen at the 
same time of day, ideally in the afternoon. 
 
2.8.2.3 The Montreal Imaging Stress Task (MIST) 
Designed to induce stress in a functional neuroimaging environment, the Montreal Imaging 
Stress Task (MIST) presents mental arithmetic tasks on a computer screen during the scanning 
procedure. Experimental and baseline conditions differ in task difficulty as well as visual and 
verbal feedback by the experimenter. In addition, task difficulty in the experimental condition 
is constantly adjusted by the computer to be just beyond the participant’s highest 
performance level (Dedovic et al., 2005).  
 
 
2.8.2.4 The Experience Sampling Method 
Responses to naturally occurring stressors have been examined using the Experience Sampling 
Method (ESM), a structured diary technique (Myin-Germeys and van Os, 2007). Briefly, 
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participants are prompted by a digital wristwatch at random intervals throughout the day and 
asked to describe stressful experiences, provide ratings of current mood and symptoms, and 
collect a salivary cortisol sample. 
 
2.8.2.5 Pharmacological cortisol challenges 
Finally, changes in HPA axis function can be assessed following administration of a 
pharmacological agent. The most commonly utilized method is the dexamethasone 
suppression test (DST), which involves administering dexamethasone (a synthetic 
glucocorticoid) in order to determine whether the HPA axis negative feedback system is 
effective in suppressing cortisol secretion. Another laboratory procedure involves 
administering 2-deoxy-D-glucose (2-DG), a glucose analogue that blocks glycolysis and induces 
cortisol secretion. 
 
2.8.3 Statistical complexities 
There are a number of statistical complexities associated with the measurement of change in 
bio-behavioral variables, including cortisol (Rogosa, 1995, Burt and Obradović, 2013, Chiolero 
et al., 2013). According to the ‘law of initial values’, the magnitude of stress induced change in 
cortisol can be inversely related with the baseline or ‘initial’ cortisol level (Balodis et al., 2010, 
Miller et al., 2013). As a consequence, individuals characterized by chronically elevated 
cortisol secretion may not show an increased experimental stress-induced cortisol response. 
To address this problem, Miller and colleagues (Miller et al., 2013) recommend alternative 
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statistical approaches to indexing cortisol responsivity, including, autoregressive latent 
trajectory (ALT) mixture models and baseline-adjusted log-transformed criteria that reduce 
false-negative classification of subjects as non-responders. However, these approaches have 
not yet been applied to data from stress-induction paradigms with psychotic, CHR or GHR 
samples. 
 
2.8.4 The impact of confounding factors 
Both hyper- and hypo-activation of the HPA axis have been associated with similar 
pathological outcomes (Heim et al., 2000a, Fries et al., 2005, Miller et al., 2007). Similarly, 
repeated measures over days or weeks with the same method do not guarantee identical 
results. These discrepancies in HPA axis activation may be a function of habituation, 
personality, situational factors (Pruessner et al., 1997a) or increasing age (Lupien et al., 1994); 
Holtzman et al., 2013; (Platje et al., 2013). Finally, given the novelty and potential 
stressfulness of research participation, baseline cortisol levels observed in the laboratory may 
be elevated compared to the level that would have occurred in a natural environment. It is not 
clear, therefore, that a ‘true’ baseline stress measure can be obtained in the laboratory.  
 
2.8.5 Summary 
In summary, researchers should be aware that, on the one hand, cortisol levels obtained with 
varying methods, at different times of the day, in the form of single or repeated measures, at 
baseline or in response to stimulation, are likely to entail different mechanisms and yield 
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different results (Buchanan et al., 2004, Wolf et al., 2005, Buchanan et al., 2009). On the other 
hand, awareness and control of subjective, situational and methodological confounds is 
essential to achieve valid and reproducible results.  
 
 
3. Research Update on HPA Axis Function among those with Psychosis and At-Risk for 
Psychosis 
As noted in previous reviews (Walker and Diforio, 1997, Walker et al., 2008), research has 
provided ample evidence of cortisol abnormalities among individuals with established 
psychosis. However, in accordance with the clinical staging model of psychosis, it has been 
proposed that subtle neurobiological abnormalities should be detectable in early illness phases 
and evolve as the illness progresses, thereby constituting potential predictors of transition to 
psychosis (McGorry, 2013). This has sparked an interest in the investigation of HPA axis 
function prior to illness onset among individuals at putative prodromal phases or at elevated 
risk for the disorder.  
In the past, the identification of at-risk individuals focused primarily on those at putative GHR 
due to a family history of illness. Given the limited generalizability of this approach (i.e., the 
majority of individuals with schizophrenia do not have a first-degree relative with the disorder 
and the majority (>80%) of biological offspring of patients do not develop psychosis) 
(Lichtenstein et al., 2009), other strategies focusing on clinical presentation have emerged. The 
most widely-implemented of these is the CHR approach, examining help-seeking adolescents 
and young adults who display symptoms consistent with the prodromal phase of illness, that 
typically precedes the onset of florid psychosis and is characterized by attenuated psychotic 
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symptoms, as measured by standardized diagnostic interviews and criteria (Woods et al., 2009, 
Fusar-Poli et al., 2013). Risk rates for subsequent psychosis in those who meet CHR criteria 
range between 20 and 40% over two years (Addington and Heinssen, 2012, Fusar-Poli et al., 
2012a), but can be even lower (Pruessner et al., 2015a). 
Researchers have also studied non-help-seeking samples who report subclinical psychotic 
symptoms which, although not uncommon, confer elevated risk for psychosis (Kaymaz et al., 
2012). Other studies focus on individuals who are at elevated risk for psychosis because they 
meet diagnostic criteria for schizotypal personality disorder (SPD), a disorder assumed to be on 
the schizophrenia spectrum because it is more often present in the biological relatives of 
schizophrenia probands.  
In the following sections, we review the results of studies published since our 2008 review, 
examining three indices of HPA axis function among psychotic patients and those at risk for 
psychosis: (i) baseline cortisol, (ii) the cortisol awakening response, and (iii) cortisol responses 
to stress and pharmacologic challenge. The results suggest that these measures index different 
aspects of the stress response and have partially independent determinants. 
 
3.1 Baseline Cortisol 
Recent studies of baseline cortisol levels in psychosis generally yielded results consistent with 
our previous review (Walker et al., 2008), showing elevated cortisol levels in patients with 
established psychosis relative to healthy controls in blood (Venkatasubramanian et al., 2010, 
Yildirim et al., 2011, Girshkin et al., 2014). Similarly, recent systematic reviews and subsequent 
studies also indicate that plasma/serum cortisol levels are elevated among individuals 
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experiencing their first episode of psychosis (FEP) (Borges et al., 2013, Karanikas et al., 2014, 
Carol and Mittal, 2015, Dogan Bulut et al., 2016). However, not all studies have replicated these 
findings, particularly when medication effects were not controlled for (Strous et al., 2004, 
Garner et al., 2011, Garcia-Rizo et al., 2012, van Venrooij et al., 2012). Such medication effects 
on baseline cortisol levels become most evident when reviewing the literature on studies 
measuring cortisol in saliva. Here, higher diurnal cortisol levels relative to controls were 
observed only among antipsychotic-naïve or minimally-treated first-episode psychosis patients 
(Gunduz-Bruce et al., 2007, Mondelli et al., 2010a). In contrast, studies of first-episode patients, 
the majority of whom were treated with antipsychotic medication, did not observe elevated 
diurnal cortisol AUC (Hempel et al., 2010). Indeed, the medicated patients were found to show 
a sharper decrease in cortisol levels throughout the day (Hempel et al., 2010). Accumulated 
evidence thus indicates that cortisol levels during the day are elevated among individuals with 
psychosis and that inconsistent findings across studies may reflect the dampening effects of 
antipsychotic medication. 
Elevated baseline cortisol levels in both blood and saliva have similarly been observed among 
individuals at risk for psychosis, although the consistency of this finding varies (Aiello et al., 
2012, Carol and Mittal, 2015, Karanikas and Garyfallos, 2015). Two recent studies reported 
higher cortisol levels in a single salivary sample among CHR youth relative to controls 
(Sugranyes et al., 2012, Carol and Mittal, 2015). Again, this group difference was more 
pronounced among those who were medication-free (Sugranyes et al., 2012). Similarly, studies 
examining salivary cortisol at multiple time-points throughout the day have observed elevated 
levels among youth at CHR for psychosis (Walker et al., 2013b), adolescents with SPD 
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(Weinstein et al., 1999, Walker et al., 2001, Mittal et al., 2007), and young adults with high 
scores on a measure of subclinical psychotic symptoms (Mittal et al., 2013). 
In contrast, a study examining fasting morning levels of both salivary and plasma cortisol 
obtained at a single time-point in a laboratory setting reported that CHR youth did not differ 
significantly from healthy controls on either measure (Labad et al., 2015). Similarly, two recent 
studies, which implemented a home saliva sampling protocol, failed to observe increased 
diurnal cortisol among CHR youth (Day et al., 2014) or children with either a family history of 
illness or multiple antecedents of schizophrenia (Cullen et al., 2014b). It is possible that the 
uncontrolled in-home environment and extended sampling period might increase error 
variance and inter-individual variation in cortisol measurement, which would diminish power to 
detect group differences.  
It appears that findings furthermore differ between studies with GHR and CHR groups. Two 
studies of individuals with a family history of illness, one examining serum cortisol in a non-
fasting blood sample (Yildirim et al., 2011), and the other in multiple salivary cortisol samples 
obtained throughout the day (Collip et al., 2011) both showed elevated cortisol levels in 
relatives compared to controls. However, four studies utilizing fasting plasma cortisol samples 
did not (Marcelis et al., 2004, Spelman et al., 2007, Brunelin et al., 2008, Yang et al., 2012). 
Indeed, lower cortisol levels (albeit non-significantly lower) were observed among relatives in 
three of these studies. As noted above, however, most with a family history of psychosis do not 
go on to develop a psychotic disorder. Thus the majority of GHR subjects will be false positives. 
In contrast, the rate of conversion to psychosis is higher in CHR samples and they are, by 
definition, characterized by the presence of a clinical syndrome. 
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A recent study directly compared salivary cortisol levels in samples collected at a single time-
point (09:00 am) in FEP patients, individuals at CHR, and help-seeking individuals who did not 
meet CHR criteria (Chaumette et al., 2016). Interestingly, cortisol levels were not significantly 
different across the three groups, even after adjusting for a range of potential confounders 
(including medication use). A problem with most cortisol measures at a fixed time point in the 
morning is that they may have been confounded by the cortisol awakening response. However, 
it cannot be excluded that elevations in basal cortisol reflect general distress associated with 
mental health problems rather than psychosis risk per se.  
Longitudinal studies of at-risk youth have also yielded somewhat inconsistent findings. A study 
of at-risk youth who were assessed at baseline and at 7- and 12-month follow-ups, showed that 
cortisol levels at baseline did not differ between converters and non-converters, but that 
converters showed higher cortisol levels at follow-up assessments (Walker et al., 2010). 
However, a subsequent study examining a larger sample of CHR youth indicated that cortisol 
levels at study onset were significantly elevated among those who transitioned to psychosis 
within two years relative to healthy controls and CHR youth whose symptoms had remitted 
(Walker et al., 2013b). In contrast, a recent study of CHR subjects failed to show an association 
between transition to psychosis and cortisol levels measured at the time of recruitment, 
however some were on antipsychotics (Chaumette et al., 2016). Two recent studies employing 
hair cortisol showed that elevations in basal HPA axis activity precede the onset of psychosis 
(Andrade et al., 2016) and mark an acute illness course as opposed to remission (Streit et al., 
2016). 
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3.2 Cortisol Awakening Response 
Recently, the focus of research related to HPA axis function in psychosis has shifted to the 
investigation of the cortisol awakening response (CAR), but the number of studies is limited. 
Again, findings here are somewhat inconsistent, and the influence of confounding factors is 
likely. The most influential study in this area to date reported a blunted CAR among first-
episode patients relative to controls (Mondelli et al., 2010a). In contrast, several other studies 
did not observe a significant group difference in the CAR in FEP patients (Pruessner et al., 2008, 
Hempel et al., 2010, Pruessner et al., 2013b, Girshkin et al., 2016) and in patients with 
established psychosis (Monteleone et al., 2015) compared to healthy controls. A series of 
studies by the first author suggests that any indication of such group differences is driven by 
confounding factors such as sex differences and the time of awakening (Pruessner et al., 2008, 
Pruessner et al., 2013b, Pruessner et al., 2015b). In line with this notion, other studies suggest 
that a blunted CAR might be associated with factors such as a poor response to antipsychotic 
medication (Mondelli et al., 2015), cannabis use (Monteleone et al., 2014) or simply poor 
sampling adherence (Berger et al., 2016). 
 
Few studies have examined the CAR in at-risk individuals. Two studies observed a blunted CAR 
compared to controls, one among CHR youth (Day et al., 2014), and another in children aged 
11-14 years (Cullen et al., 2014b). In contrast, a blunted CAR was not observed among children 
at-risk due to the presence of multiple antecedents of schizophrenia (Cullen et al., 2014b) and 
in another recent study in CHR individuals (Pruessner et al., 2016). However, in line with our 
 
 
31 
findings in FEP patients, male patients showed a trend for blunted cortisol levels following 
awakening compared to female patients (Pruessner et al., 2016). Similarly, another recent 
study found no difference in cortisol levels over two hours after awakening between CHR 
individuals and controls, but observed a significantly blunted cortisol response in male 
compared to female patients (Carol et al., 2016). Yet another recent study observed an 
increased CAR in at-risk youth who transitioned to psychosis within one year relative to both 
CHR youth who did not transition and healthy controls (Labad et al., 2015). Considering the 
conflicting evidence, a recent systematic review and meta-analysis on the CAR in patients at 
different stages of the psychosis continuum comes to the conclusion that the CAR is attenuated 
in patients with established psychosis, but not in individuals at CHR (Berger et al., 2016). As 
acknowledged by the authors themselves, the number of studies on the CAR in this area is 
limited, and factors such as comorbidities, adherence and response to medication, and 
adherence to sampling procedures will need to be controlled for in future studies (Berger et al., 
2016). 
 
3.3 Cortisol Responses to Stress and Pharmacologic Challenge  
Studies investigating the cortisol response to acute challenges across the psychosis spectrum 
are also few in number. Confirming previous reports (Jansen et al., 1998, Jansen et al., 2000), 
recent studies have reported a blunted cortisol response to a public speaking task in patients 
with chronic schizophrenia (Brenner et al., 2009) and in medication-naïve FEP patients (van 
Venrooij et al., 2012) relative to healthy controls. Despite the similar findings in medicated and 
non-medicated patients, antipsychotic use appears to contribute to a blunted cortisol response 
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to stress (Houtepen et al., 2015). Similar to findings in established psychosis, the cortisol 
response to the TSST has also been shown to be blunted among antipsychotic-naïve CHR youth 
relative to controls (Pruessner et al., 2013a). In contrast, a study using a mental arithmetic task 
during a positron-emission tomography (PET) scan, found a decrease in salivary cortisol during 
the task in controls and no change in CHR youth (Mizrahi et al., 2012). In an earlier study using 
this stress paradigm during a PET scan, both youth with schizotypal traits and healthy controls 
showed a significant cortisol response, with no significant difference between the groups 
(Soliman et al., 2008). The cortisol response in these latter studies might have been confounded 
by the potentially stress-inducing environment of a PET scan. Furthermore, small subject 
numbers in these studies indicate the need for further validation of the results.  
Using the experience sampling method (ESM), a study of an adult GHR sample observed an 
increase in the cortisol response to unpleasant events, that was not present among healthy 
controls (Collip et al., 2011). However, in a subsequent report based on a subsample from this 
study, the cortisol response to daily stressors in both patients and their siblings did not differ 
from that of healthy controls (Habets et al., 2012), which may reflect a lack of statistical power 
due to the smaller sample size.  
Early studies employing the Dexamethasone suppression test (DST) had reported that patients 
with schizophrenia (the majority of whom were receiving antipsychotic medication) were more 
likely to be classified as dexamethasone ‘non-suppressors’ than controls (Banki et al., 1985, 
Baumgartner et al., 1986, Lammers et al., 1995). Recently, higher post-dexamethasone cortisol 
levels and higher rates of dexamethasone non-suppression relative to controls have also been 
reported in studies of patients with psychotic depression (Schatzberg, 2015). In contrast, the 
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only study comparing first-episode psychosis patients to controls reported higher rates of 
cortisol hyper-suppression in patients (Phassouliotis et al., 2013). A small sample (n=12) study 
by this group also reported that, contrary to hypotheses, antipsychotic-naive CHR youth who 
later transitioned to psychosis (n=3) had lower post-dexamethasone cortisol levels than those 
who did not (Thompson et al., 2007a). While these two reports of increased cortisol hyper-
suppression are similar to findings observed in patients with PTSD, and may therefore indicate 
enhanced inhibition of cortisol via negative feedback (Yehuda, 2001, 2002), they should be 
interpreted with caution due to the small sample sizes and the fact that some subjects were on 
antipsychotic medication. Results of the 2-deoxy-D-glucose (2-DG) test on cortisol levels have 
been inconclusive (Elman et al., 1998, Marcelis et al., 2004, Mitropoulou et al., 2004, Brunelin 
et al., 2008), and recent findings are lacking. Incongruent findings likely reflect differences in 
methodology and sample characteristics.  
 
3.4 Specificity of HPA axis abnormalities to psychosis 
Abnormal cortisol levels have also been observed among other psychiatric disorders, most 
notably, depression and post-traumatic stress disorder (PTSD). Recent meta-analyses indicate 
that individuals with depression are characterized by elevated diurnal cortisol levels (Stetler 
and Miller, 2011), a blunted cortisol response to stress and impaired stress recovery compared 
to non-depressed controls (Burke et al., 2005). Further, research has shown that depressed 
patients with psychosis have higher cortisol levels than nonpsychotic depressed patients and 
healthy controls (Keller et al., 2016). Whilst the CAR has been less frequently examined in this 
population, several studies have observed an increased CAR among both adolescents and 
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adults with depression (Bhagwagar et al., 2003, Dienes et al., 2013, Ulrike et al., 2013) and 
individuals with subclinical depression symptoms (Pruessner et al., 2003b) relative to healthy 
controls. In contrast, there is evidence that individuals with PTSD, like those with psychosis, are 
characterized by a blunted CAR (Chida and Steptoe, 2009). However, decreased cortisol levels 
during the day have been consistently reported among PTSD patients relative to controls 
(Morris et al., 2012). Yet another picture emerges in panic disorder patients, who show little or 
no alteration in basal cortisol levels and a normal CAR, but a distinctive non-responsiveness to a 
psychosocial stressor (Petrowski et al., 2010). Thus, the pattern of cortisol abnormalities 
observed among individuals with psychosis shares some features with other disorders, yet the 
elevated diurnal cortisol levels in combination with a blunted CAR appear to reflect a specific 
profile that is distinct from that observed in depressed and PTSD populations (Borges et al., 
2013). 
 
3.5 Sex differences in HPA axis function in psychosis 
As described in section 2.6, there are well-documented sex differences in the course of 
schizophrenia and other psychotic disorders. There are also some normative sex differences in 
HPA function and cortisol secretion (Paris et al., 2010). In the context of various health and 
psychopathological conditions, both elevated and blunted CARs have been reported (Kudielka 
and Wust, 2010). Interestingly, low grade depressive symptomatology in non-clinical samples 
has been associated with an elevated CAR in males (Pruessner et al., 2003b) and a blunted CAR 
in females (Stetler and Miller, 2005), suggesting that the consideration of sex differences might 
help to explain inconsistent findings.  
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In patients with psychosis (Girshkin et al., 2014) and CHR samples (Walker et al., 2013) no sex 
differences have been reported for baseline cortisol measures; however, sex differences might 
become evident when the HPA axis is stimulated (by awakening or psychological/mental 
challenges). Indeed, Pruessner et al. recently observed a blunted CAR in male patients 
compared to female FEP patients (Pruessner et al., 2008, Pruessner et al., 2013b, Pruessner et 
al., 2015b) and compared to male healthy controls (Pruessner et al., 2015b). Similarly, a recent 
study in individuals at CHR found a trend for a smaller CAR in male compared to female patients 
(Pruessner et al., 2016), and a study measuring cortisol over three time points in the morning 
observed flat cortisol levels in male compared to female CHR subjects (Carol et al., 2016). In 
these studies, no significant sex differences in the CAR were observed in the control group, or 
when female patients were compared with same-sex controls. Our research furthermore 
demonstrated an association between attenuated cortisol levels post awakening and smaller 
hippocampal volume, again predominantly in male patients (Pruessner et al., 2015b). 
Interestingly, sex differences in the CAR were not reported in other recent studies including FEP 
patients (Mondelli et al., 2010a), individuals at CHR (Day et al., 2014) and children at familial 
high risk for psychosis (Cullen et al., 2014b).  
With respect to mental challenge tasks, Brenner and colleagues reported higher cortisol levels 
(both prior to and during the task) in male relative to female participants across both patients 
with established psychosis and controls (Brenner et al., 2009). These authors had observed a 
blunted cortisol response to stress in the total patient group compared to controls (described 
above), suggesting that alterations in HPA axis function related to pathologic processes are 
superimposed on existing sex differences. However, two other recent studies investigating the 
cortisol response to mental challenge did not find sex differences in FEP (Mizrahi et al., 2012) 
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and CHR patients (Pruessner et al., 2013a). Possible determinants of the scarcity of sex 
differences related to HPA axis function in psychosis might be the generally small number of 
participants and relatively smaller number of female than male patients in these studies, often 
resulting in a lack of statistical power in sex specific analyses. Further, there is evidence that 
stress-induced cortisol levels in women vary with menstrual cycle phase (Kudielka and 
Kirschbaum, 2005, Walder et al., 2012), impeding the chances to find significant sex differences 
when this factor is not controlled. Clearly, further investigation of sex differences with respect 
to HPA axis function in psychosis and high-risk populations is warranted. 
 
- - - - - - - - - - - - 
Insert Table 1 
- - - - - - - - - - - - 
 
3.6 Summary 
Table 1 provides a summary of reported cortisol abnormalities among those with established 
psychosis and those at-risk for the disorder. As illustrated, there is evidence that patients with 
chronic schizophrenia and first-episode psychosis are characterized by elevated baseline 
cortisol levels, but that this finding is less consistent among patients treated with antipsychotic 
medication. Baseline cortisol elevations have similarly been reported among youth at CHR for 
psychosis and adolescents with SPD; however, findings among GHR individuals and children 
presenting multiple antecedents of schizophrenia have been inconsistent. This is perhaps to be 
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expected, given that the rate of conversion to psychosis is much lower in GHR subjects when 
compared to CHR subjects (Woods et al., 2009). Thus, GHR samples are less ‘enriched’ in that 
they include a smaller proportion of individuals who will subsequently be diagnosed with a 
psychotic disorder. 
Findings relating to the CAR are mixed. While several studies have observed a blunted CAR 
among patients with psychosis and individuals at CHR for the disorder, relative to healthy 
controls, other studies have observed no group differences or found an increased CAR in 
individuals at CHR compared to controls. A recent systematic review and meta-analysis on the 
subject comes to the conclusion that the CAR is attenuated in established and first episode 
psychosis, but not in individuals at CHR (Berger et al., 2016).  
As yet, there is little evidence of heightened HPA responsivity from experimental studies using 
stress or pharmacologic challenge. Generally, patients with psychosis appear to show a blunted 
cortisol response during psychosocial stressor tasks and increased rates of cortisol ‘non-
suppression’ to the DST. These trends have not been consistently replicated in at-risk samples. 
Studies administering 2-DG have likewise generated contrasting findings. As described in 
section 2.8.3, however, measurement of HPA responsivity to challenge is complicated by 
individual differences in baseline levels. To date, studies of responsivity in psychotic and high-
risk samples have not employed the statistical approaches that appear optimal for addressing 
this problem (Miller et al., 2013). In sum, research findings to date have provided fairly 
consistent evidence that elevated baseline cortisol levels characterize both psychosis patients 
and CHR individuals, but studies of the CAR and HPA axis responses have been somewhat 
inconsistent. Conflicting findings in both groups might be explained by the use of medication or 
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methodological differences such as measurement time (morning, diurnal), measurement 
frequency and pattern (e.g. single, repeated), location (home, laboratory), sampling method 
(saliva, blood), sampling adherence, or group characteristics (family history of psychosis, illness 
stage, sex differences). Further studies using more stringent methodological and statistical 
approaches are needed. 
 
 
4. Stress, Cortisol, and Symptoms 
4.1 Stress exposure, perceived stress and early life adversity 
There is now substantial evidence to support the notion that psychosocial stress contributes to 
the onset and exacerbation of psychotic symptoms in vulnerable individuals. An early study 
demonstrated that both major life events and subjective experiences of stress predicted poor 
clinical outcome among patients with established schizophrenia, although perceived stress 
showed a more reliable relationship to symptomatology than major life events (Malla and 
Norman, 1992). This has been supported by numerous subsequent studies (Holtzman et al., 
2013). Similarly, CHR patients who later converted to psychosis reported a greater number of 
life events, and perceived these events as more stressful, compared to healthy controls and 
CHR subjects whose symptoms remitted (Trotman et al., 2014). Perceived stress levels in CHR 
patients are generally high (Moskow et al., 2016), and in some studies they even exceed ratings 
in FEP patients (Pruessner et al., 2011, Palmier-Claus et al., 2012).  
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Recent research has also demonstrated a relationship of higher perceived stress with 
depression and positive symptoms in both at-risk samples (Pruessner et al., 2011, Tessner et al., 
2011, Palmier-Claus et al., 2012, Devylder et al., 2013, Cullen et al., 2014a) and first episode 
psychosis patients (Raune et al., 2006, Lataster et al., 2013). However, as noted above, elevated 
stress levels may be secondary to illness related factors, rather than causal. Similarly, at the 
neural level, while there has been an emphasis on the role of cortisol in the expression of 
symptoms through effects on dopaminergic pathways (“bottom-up” model), it is also possible 
that symptoms and corresponding neurotransmitter activity affect HPA axis activity (“top 
down” model) (Belvederi Murri et al., 2012). 
It has been suggested that especially earlier and/or longer term, rather than acute or recent 
perceived stress affects pathophysiological processes in psychosis (Alameda et al., 2015, 
Nugent et al., 2015). Here, a well-documented risk factor for psychosis is early life adversity 
(Gibson et al., 2016). A large-scale meta-analysis including 45,441 individuals concluded that 
childhood trauma is strongly linked to increased risk of developing a psychotic disorder, with an 
overall effect of OR=2.78 (95% CI=2.34-3.31) (Varese et al., 2012). This association was still 
significant after adjustment for genetic risk, supporting the notion of a causal relation between 
early life adversity and psychosis (van Winkel et al., 2013). A recent study of CHR individuals 
showed that a history of childhood sexual abuse increased the transition rate to psychosis up to 
2-4 times (Thompson et al., 2014). Other research suggests that childhood trauma particularly 
affects positive and dysthymia symptoms (Ruby et al., 2015) and that patients who have 
experienced childhood trauma show delayed symptom remission (Aas et al., 2016). Of course, 
the adverse effects of childhood trauma are not specific to psychosis, and victims of childhood 
trauma show a range of symptoms and syndromes (van Nierop et al., 2014, Gibson et al., 2016).  
 
 
40 
Early life stress in particular appears to have enduring effects on the brain and stress regulatory 
systems, including the autonomic, endocrine and immune systems, which may lead to a lifelong 
increased vulnerability to subsequent stress and consequences for detrimental long-term 
health outcomes (Heim and Binder, 2012). Both animal (Liu et al., 1997, Anisman et al., 1998) 
and human (Devylder et al., 2013, Trotman et al., 2014) studies have shown that previous 
exposure to stressful events can lead to stress-sensitization and dysregulation of the HPA 
response when confronted with subsequent stressors, both of which are believed to be critical 
contributors to the development of psychosis. Trauma victims not only responded with more 
subjective distress to stressful experiences later in life (Veling et al., 2016), the experience of 
early life adversity also predicted attenuated cortisol responses to a public speaking task in a 
dose-dependent fashion (Lovallo et al., 2012). Similarly, a study of FEP patients recently showed 
an association between poor parental bonding, an indicator for early life adversity, and a 
blunted cortisol awakening response (Pruessner et al., 2013b). Some studies report 
hyperactivity of the HPA axis following early life adversity. Both the timing of the stressor 
(Bosch et al., 2012) and the type of stressor (Essex et al., 2011) may play a role for such long-
term effects on HPA axis function.  
 
4.2 Cortisol and psychotic symptoms and syndromes 
If, as proposed by the neural diathesis stress model (Walker and Diforio, 1997, Walker et al., 
2008), activation of the HPA axis mediates the relation of stress with symptom exacerbation, 
one would expect to find associations between indices of HPA axis and symptom severity or 
other important outcome measures. However, as discussed in section 2.3, medication and 
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diagnostic and sampling criteria inevitably constrain the range of symptom severities 
represented in clinical research samples, and this is especially true of positive symptom 
measures in studies of psychosis. Likely related to this limitation, research findings in this area 
are mixed. While some cross-sectional studies have observed a modest relationship between 
basal cortisol and psychotic symptom severity (Walker and Diforio, 1997, Walker et al., 2008), 
several other studies of patient samples have not (Ryan et al., 2004, Venkatasubramanian et al., 
2007, Yilmaz et al., 2007, Pruessner et al., 2013b, Dogan Bulut et al., 2016). Studies on the CAR 
in FEP patients found either no association with symptoms (Mondelli et al., 2010a, Pruessner et 
al., 2013b) or only a trend level relationship between cortisol levels and poor global functioning 
(Pruessner et al., 2015b). As a measure of cortisol changes over time, hair cortisol 
concentrations (HCC) over the past three months correlate with general psychopathology 
(Andrade et al., 2016) and HCC at the time of admission can differentiate between in- and 
outpatients with psychosis (Streit et al., 2016). 
A similarly diverse picture regarding the association between stress and symptoms can be 
observed in CHR populations. Findings from the North American Prodrome Longitudinal Study 
(NAPLS) showed small but significant positive correlations between heightened basal cortisol 
levels and positive, negative, and general symptom severity at baseline (Walker et al., 2013b). A 
study utilising the ESM method among siblings of patients with psychosis observed that 
momentary increases in both psychotic symptoms and negative affect were associated with 
increased cortisol levels in siblings, but not healthy controls (Collip et al., 2011). However, 
several other cross-sectional studies did not find relationships between cortisol levels and 
psychotic symptom severity in CHR patients (Sugranyes et al., 2012, Pruessner et al., 2013a, 
Day et al., 2014). A recent review concluded that a cross-sectional relation between cortisol 
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levels and measures of psychotic symptom severity could not be confirmed for the majority of 
studies of individuals at-risk for psychosis, but that there was a more consistent association 
with anxiety and subjective stress (Karanikas and Garyfallos, 2015). A different picture emerged 
in a recent longitudinal study, where Walker et al. found that higher baseline cortisol in CHR 
subjects predicted transition to psychosis over time (Walker et al., 2013b). 
 
In summary, cross-sectional studies in clinical samples of psychotic and CHR patients reveal 
inconsistent and nonspecific positive relations between cortisol and symptom severity. The 
findings are consistent with the assumptions that stress and cortisol release have nonspecific 
effects on the expression of vulnerability for mental illness, and are thus related to multiple 
symptom dimensions (Belvederi Murri et al., 2012). This pattern is not surprising in light of the 
varied symptom and HPA axis measures, the diverse samples utilized in this research, and the 
limitation that the restricted range of positive symptom severity in samples of psychotic and 
CHR patients reduces statistical power to detect associations with biomarkers. Furthermore, 
longitudinal studies might have greater power than cross-sectional studies for detecting 
relations among biomarkers and symptoms. 
 
 
5. Stress, Glucocorticoids and neuroimaging findings 
Structural brain abnormalities are a common finding in psychosis and include reduced total 
grey and white matter volume in various brain regions as well as increased ventricular volume 
(Steen et al., 2006, Bora et al., 2011, De Peri et al., 2012, Cannon et al., 2015). Neuroanatomical 
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abnormalities are already present prior to illness onset among individuals at CHR (Pantelis et 
al., 2009), and appear to progress over time, especially in those who transition to psychosis 
(Borgwardt et al., 2008, Takahashi et al., 2009b, Smieskova et al., 2010, Mechelli et al., 2011, 
Dazzan et al., 2012, Ziermans et al., 2012, Cannon et al., 2015). Moreover, a subset of these 
neuroanatomical abnormalities (predominately within the temporal lobe) have been observed 
among children aged 9-13 years within the general population who report subclinical psychotic 
symptoms (Jacobson et al., 2010, Cullen et al., 2013).  
 
Given the role of certain neuroanatomical regions and endocrine glands in HPA axis regulation, 
it is assumed that changes in their volume will be associated with indices of HPA axis activity. In 
particular, hippocampal and pituitary volume (i.e., structures involved in moderating HPA axis 
activity) would be expected to be linked with measures of HPA axis function, although volume 
reductions in other regions (e g., amygdala) have also been observed in psychosis (Aas et al., 
2012b, Watson et al., 2012). In the following section, we will review the literature on structural 
abnormalities in psychosis and at risk states for psychosis, with an emphasis on the 
hippocampus and the pituitary. 
 
5.1 Hippocampal volume abnormalities in psychosis 
Hippocampal volume (HV) reduction has emerged as one of the most replicated structural brain 
abnormalities in psychosis (Velakoulis et al., 2006, Adriano et al., 2012). Hippocampal 
abnormalities can already be observed at the CHR and FEP stage and there appears to be 
further shrinkage over time as the disease progresses (Giedd et al., 1999, Velakoulis et al., 
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1999, Pantelis et al., 2003a). It has been suggested that these changes might be related to 
hormonal changes in response to the stress of transition to psychosis (Pantelis et al., 2007).  
In these early stages, the left hippocampus appears to be more affected by volume decline than 
the right (Velakoulis et al., 2006, Buehlmann et al., 2010, Malchow et al., 2013). Evidence for 
the relevance of the left hippocampus in psychosis stems also from studies showing that 
particularly reduced left HV is correlated with the number of previous psychotic episodes in 
schizophrenia patients (Hyza et al., 2014) and that CHR patients who later developed psychosis 
show altered metabolic activity in the left hippocampal head (Wood et al., 2010).  
Challenging the notion of a progressive course of brain changes related to illness onset, two 
recent studies in CHR patients found a decrease in HV independent of transition status (Wood 
et al., 2010, Walter et al., 2012). Furthermore, reduced HV has been found in healthy co-twins 
of probands (van Erp et al., 2004) and non-psychotic offspring of schizophrenia patients 
(Keshavan et al., 2002), demonstrating an influence of genetic and/or shared environmental 
factors on HV in these individuals. A longitudinal study in FEP patients suggested that volume 
reduction in the superior temporal cortex and hippocampus might be reversible dependent on 
remission status (Schaufelberger et al., 2011). This notion is consistent with evidence from 
research on stress hormone related conditions, such as Cushing’s syndrome (McEwen, 1999, 
Starkman et al., 1999, Starkman et al., 2003). To date, only one study found larger HV to be 
predictive of transition to psychosis (Phillips et al., 2002). 
HV has been found to inversely correlate with both positive and negative symptoms of 
psychosis (Watson et al., 2012, Brambilla et al., 2013, Mathew et al., 2014). In a longitudinal 
study, higher baseline positive symptoms were associated with more striatal and HV loss over 
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time (Ebdrup et al., 2011). A recent study in FEP found that smaller HV bilaterally was 
significantly related to positive psychotic symptoms and lower levels of functioning only in male 
but not in female patients (Pruessner et al., 2015b). In schizophrenia patients, volume 
reductions in hippocampal subfields CA2/3 and CA1 were found to be correlated to positive 
symptoms (Kuhn et al., 2012). In recent functional magnetic resonance imaging (fMRI) studies 
in schizophrenia patients, greater resting state activity of the hippocampus was correlated with 
more negative symptoms (Tregellas et al., 2014), and increased left hippocampal activity during 
successful encoding of words was related to positive symptoms (Zierhut et al., 2010).  
A meta-analyses on voxel-based morphometry (VBM) studies concluded that grey matter 
volume reductions in limbic system and other structures are more pronounced in male 
dominated samples of schizophrenia patients compared to gender balanced samples (Bora et 
al., 2012). While some studies found more pronounced amygdala volume reductions (Gur et al., 
2004, Niu et al., 2004, Frazier et al., 2008) and greater severity of ventricular enlargement 
(Nopoulos et al., 1997) in male compared to female patients, the majority of reports point to a 
more pronounced HV reduction in male patients, both with chronic schizophrenia (Bryant et al., 
1999, Exner et al., 2008, Irle et al., 2011, Adriano et al., 2012, Bora et al., 2012) and FEP 
(Bogerts et al., 1990, Pruessner et al., 2015b), and recently also in individuals at CHR (Pruessner 
et al., 2016).  
 
5.2 Hippocampal volume and HPA axis in psychosis 
Inverse associations between reduced HV and HPA axis dysregulation have been observed in 
various conditions including depression, PTSD and aging (Frodl and O'Keane, 2013, Wingenfeld 
 
 
46 
and Wolf, 2014). This association has been explained by the important role of the hippocampus 
in the regulation of the HPA axis (McEwen and Gianaros, 2010). At the neuronal level, chronic 
stress has been shown to cause shortening of dendrites, loss of spine synapses and suppression 
of neurogenesis in animals. While experimental animal models suggest this can be a reversible 
process, such cellular alterations are believed to be at the core of HV reductions and the 
resultant compromise of its role as a regulator of HPA axis function (McEwen and Gianaros, 
2010). 
Research on the relationship between cortisol levels and brain volume measures in psychosis is 
limited; a recent study in FEP was the first to report a correlation between higher diurnal 
cortisol levels and smaller HV in patients, but not in controls (Mondelli et al., 2010b). In 
contrast, no correlation was observed between cumulative diurnal cortisol exposure and 
volume in hippocampal subregions in a small sample of FEP patients (Gunduz-Bruce et al., 
2007). Subsequently, Pruessner et al. found a greater blunting of the CAR and smaller left HV 
particularly in male FEP patients (Pruessner et al., 2015b) and individuals at CHR for psychosis 
(Pruessner et al., 2016), and observed a significant relationship between both markers. No such 
association was observed in the healthy controls (Pruessner et al., 2015b, Pruessner et al., 
2016). Another recent study in CHR individuals using voxel-based morphometry found an 
association between an attenuated CAR and gray matter volume in parahippocampal / fusiform 
and parietal areas (Valli et al., 2016). A relationship between the CAR and HV was observed 
across both groups (CHR and controls) (Valli et al., 2016). In healthy GHR subjects, those with a 
smaller HV exhibited greater momentary cortisol levels assessed with the experience sampling 
method (Collip et al., 2013). In summary, initial evidence supports the notion that, similar to 
findings in other conditions, abnormalities in HPA axis regulation are associated with HV 
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decline. Future studies need to further investigate the implications of HV and HPA axis 
dysregulations as related markers of stress vulnerability in psychosis. 
 
5.3 Pituitary volume abnormalities in psychosis  
Cross-sectional studies indicate that pituitary volume abnormalities are present at different 
stages of psychosis but that the pattern of abnormalities (i.e., relative increases/decreases in 
volume compared to healthy controls) may change over the course of illness. Specifically, 
studies of first-episode psychosis patients have observed enlarged pituitary volume relative to 
healthy controls (Pariante et al., 2004, Pariante et al., 2005, Büschlen et al., 2011, Takahashi et 
al., 2011). In contrast, smaller pituitary volumes relative to controls have been reported among 
patients with chronic schizophrenia (Pariante et al., 2004, Upadhyaya et al., 2007). However, 
other studies have observed no pituitary volume abnormalities among patients with psychosis 
(chronic or first-episode) and healthy controls (Nicolo et al., 2010, Klomp et al., 2012). 
Furthermore, longitudinal studies following individuals from the time of their first psychotic 
episode have observed both pituitary volume increases (MacMaster et al., 2007a) and 
decreases (Nicolo et al., 2010) following antipsychotic treatment. These inconsistent findings 
may relate to differences in medication types across studies, but could also be related to sex 
differences and age effects. Pituitary volume has been shown to be larger in women compared 
to men, and increases with age are more pronounced in female patients (Doraiswamy et al., 
1992, MacMaster et al., 2007b). Such sex differences are also present in schizophrenia 
spectrum disorders (Romo-Nava et al., 2013). Thus, the extent to which the pattern of pituitary 
volume abnormalities distinguishes individuals with first-episode psychosis from those with 
chronic illness is currently unclear.  
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There is limited evidence that GHR individuals are also characterized by pituitary volume 
abnormalities. While one study of older adult relatives (predominately parents) of individuals 
with schizophrenia reported enlarged pituitary volume in this group compared to healthy 
controls (Mondelli et al., 2008); three subsequent studies of younger relatives (including 
children, adolescents, and young adults) found no such abnormalities (Habets et al., 2012, 
Cullen et al., 2015a, Shah et al., 2015a). However, Shah and colleagues (2015) observed larger 
pituitary volume among GHR adolescents and young adults who later converted to psychosis 
compared to both relatives who did not convert and healthy controls.  
Heterogeneous findings have also been reported among individuals at CHR, possibly reflecting 
differences in symptom severity and medication use across studies. While larger pituitary 
volume was observed among patients with SPD recruited from psychiatric services (85% of 
whom were treated with antipsychotic medication) relative to healthy controls (Takahashi et 
al., 2009a), a subsequent study reported smaller pituitary volume among male (but not female) 
medication-naïve SPD patients when compared to controls (Romo-Nava et al., 2013). Of the 
four studies to have examined pituitary volume in CHR youth relative to controls (Garner et al., 
2005, Büschlen et al., 2011, Takahashi et al., 2013, Walter et al., 2014) only one (Takahashi et 
al., 2013) observed significant group differences (enlarged pituitary among CHR youth). While 
CHR youth in all four samples were antipsychotic-naïve or minimally-treated, negative 
symptoms were notably higher among CHR participants in the study by Takahashi at colleagues, 
possibly reflecting more advanced illness. Moreover, while two of these studies reported that 
CHR youth who transitioned to psychosis within 1-3 years were characterized by larger pituitary 
volumes at study commencement compared to CHR individuals who did not (Garner et al., 
2005, Büschlen et al., 2011), these findings were not replicated in the two subsequent 
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investigations (Takahashi et al., 2013, Walter et al., 2014), possibly reflecting limited statistical 
power related to the small number of participants in the transitioned groups. Finally, no 
pituitary volume abnormalities were observed in a sample of children (11-14 years) at elevated 
risk for schizophrenia due to the presence of developmental antecedents of the disorder 
(Cullen et al., 2015b).  
Findings to date therefore tentatively suggest that pituitary volume abnormalities may not be 
present during the early stages of illness but may reflect more advanced or acute illness. 
However, it is important to note that, with the exception of one study of GHR youth, in which a 
positive association between pituitary volume and schizotypal symptoms was observed (Shah 
et al., 2015b), previous studies of at-risk individuals have failed to observe a correlation 
between increased pituitary volume and more severe symptoms, including positive and 
negative psychotic symptoms, anxiety, and depression (Garner et al., 2005, Mondelli et al., 
2008, Takahashi et al., 2009a, Takahashi et al., 2013, Walter et al., 2014).  
 
5.4 Pituitary volume and HPA axis function 
While it is hypothesized that the pituitary volume enlargements characterizing FEP patients and 
(some) at-risk individuals result in HPA hyperactivity, following an increase in the size and 
number of anterior pituitary corticotroph cells responsible for producing HPA axis hormones 
(Pariante, 2008), there is scant evidence to support this. In fact, the relationship between 
pituitary volume and cortisol levels has scarcely been examined among individuals with or at-
risk for psychosis, or among healthy individuals.  
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An early study of patients with depression reported that pituitary volume was positively 
associated with post-dexamethasone plasma cortisol levels after adjusting for age and sex 
(Axelson et al., 1992). However, more recently, studies of GHR individuals (Habets et al., 2012) 
and CHR youth (Thompson et al., 2007b) have observed no relationship between pituitary 
volume and daytime cortisol levels. Interestingly, a study of healthy adolescents recently 
reported that pituitary volume was positively associated with the CAR and negatively 
associated with daytime cortisol levels (Kaess et al., 2013); though both relationships were 
present only in males. Thus, it is possible that differences in the sex ratio of participants across 
studies may contribute to the heterogeneity of findings. Further work is needed to determine 
whether pituitary volume is reliably associated with HPA activity.  
Conflicting results have also been obtained in the few studies that examined the relationship 
between pituitary volume and experiences of psychosocial stress. One study using the ESM 
technique to assess emotional reactivity to stress (i.e., self-reported increases in negative affect 
in response to daily social stressors) reported a positive association between pituitary volume 
and stress reactivity among patients with psychotic disorder that was not present among their 
first-degree relatives or healthy controls (Habets et al., 2012). In contrast, a recent study of 
children aged 11-14 years reported that pituitary volume was negatively associated with both 
exposure to physical punishment and distress relating to other negative life events among 
children with a family history of schizophrenia (Cullen et al., 2015b). These associations were 
not, however, present among children at-risk due to developmental antecedents of 
schizophrenia or typically-developing children. Interestingly, this latter finding is consistent with 
a previous study of adolescents with borderline personality disorder, in which those exposed to 
childhood maltreatment were characterized by smaller pituitary volumes compared to 
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unexposed youth (Garner et al., 2007). In summary, there is no consistent evidence to suggest a 
relationship between pituitary volume with cortisol or psychosocial stress among those with, 
and at-risk for, psychosis, and further research is needed.  
 
 
6. Stress, Glucocorticoids and Cognitive function 
Neurocognitive dysfunction is a core feature of schizophrenia and other psychotic disorders. 
Relative to healthy individuals, patients are characterized by moderate-to-large deficits across 
multiple neurocognitive domains, with the most severe impairments observed in memory and 
executive function (Reichenberg and Harvey, 2007). Similar impairments, albeit smaller in 
magnitude, have also been observed among individuals at CHR (Fusar-Poli et al., 2012b), GHR 
adolescents and young adults (Agnew-Blais and Seidman, 2013) and children presenting 
developmental antecedents of schizophrenia (Cullen et al., 2010, Dickson et al., 2014). While it 
is likely that these neurocognitive deficits are influenced by genetic factors (Kahn and Keefe, 
2013), there is some evidence to suggest that psychosocial stress exposure and abnormal HPA 
axis function may be contributors.  
Animal studies indicate that stress-induced HPA axis dysfunction can lead to structural 
abnormalities in the hippocampus and medial prefrontal cortex, regions which are known to 
play a crucial role in mediating HPA axis function (Herman et al., 2005). Specifically, studies of 
rodents have observed that chronic stress and persistently-elevated glucocorticoid levels can 
cause hippocampal cell damage (Sapolsky, 2000), and are associated with structural changes in 
the medial prefrontal cortex (Cerqueira et al., 2008). Thus, the deficits in memory and executive 
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function that have been consistently observed among individuals with psychosis, may, at least 
in part, be due to the adverse effects of psychosocial stress and cortisol on the brain regions 
that support these neurocognitive functions. In support of this notion, elevated cortisol levels 
have been associated with poorer performance on tests of memory and executive function 
among individuals with schizophrenia (Walder et al., 2000), and a more blunted CAR has been 
found to correlate with greater deficits in verbal memory in FEP (Aas et al., 2011b). 
Furthermore, a study of children at elevated risk for schizophrenia (due to either a family 
history of illness or developmental antecedents of schizophrenia) observed that poorer 
performance on memory and executive function measures was associated with more abnormal 
cortisol levels (i.e., elevated baseline cortisol levels and a more blunted CAR) among at-risk 
children, but not typically-developing children (Cullen et al., 2014b).  
 
As noted above, one possible explanation for the association of cognitive performance with 
cortisol among individuals with, and at-risk for, psychosis is that HPA axis dysfunction, caused 
by exposure and/or reactivity to psychosocial stress, may have a direct effect on these cognitive 
abilities via the effects of cortisol on the brain structures supporting these functions. However, 
the extent to which the observed associations between neurocognitive functions and cortisol 
are triggered by psychosocial stress exposure is currently unclear. While some studies of 
individuals with schizophrenia have reported greater impairments in memory and executive 
function among those exposed to childhood maltreatment (Lysaker et al., 2001, Aas et al., 
2011a, Shannon et al., 2011, Aas et al., 2012b), other studies have observed no association 
between psychosocial stress exposure (including childhood maltreatment) and neurocognitive 
deficits among individuals with psychosis (Schenkel et al., 2005, Aas et al., 2011c, Sideli et al., 
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2014). Indeed, Aas and colleagues reported that psychosocial stress exposure (childhood 
trauma, stressful life events, and perceived stress) was associated with poorer neurocognitive 
function among healthy individuals, but not among individuals with first-episode psychosis (Aas 
et al., 2011b), a finding that was replicated in a larger investigation of FEP patients in this study 
(Sideli et al., 2014). A similar association was observed in a study of schizophrenia patients 
(McCabe et al., 2012), in which a negative relationship was reported between exposure to 
childhood adversity and IQ among healthy controls, but not among patients. However, in two 
different studies, Aas and colleagues observed that childhood trauma was correlated with 
poorer neurocognitive performance in chronic schizophrenia and bipolar patients (Aas et al., 
2012c) and among male FEP and affective psychosis patients (Aas et al., 2011a). Thus, the 
inconsistency in findings across studies may be due to variability in patient characteristics 
across studies and/or differences in the specific psychosocial stressors examined. 
The lack of consistent findings of an association between psychosocial stress and cognitive 
function suggests that, if abnormal cortisol levels do directly contribute to neurocognitive 
deficits in individuals with psychosis, this may not be driven by increased exposure or reactivity 
to psychosocial stressors. Alternatively, the association between neurocognitive function and 
cortisol levels observed in those with, and at-risk for, psychosis may be indirect. Indeed, it is 
possible that the association reflects underlying dysfunction in the hippocampus and medial 
prefrontal cortex, regions which are densely populated with glucocorticoid receptors and 
known to play a crucial role in mediating HPA axis function (Herman et al., 2005). Thus, among 
those with, or on the trajectory to, psychosis, abnormal neurodevelopmental processes 
(possibly triggered by genetic factors or early environmental insults) may have affected the 
functional integrity of the brain structures that mediate both HPA axis function and 
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neurocognitive performance, thereby resulting in the observed correlations between these two 
features of psychosis. 
 
 
7. Stress, Glucocorticoids and Neurotransmitters in Psychosis 
Recent neuroimaging research has provided greater insights into dopamine (DA) activity and its 
relation with stress and HPA function in psychosis. Increased DA synthesis capacity and release 
are reported in both psychotic patients (Howes et al., 2009a, Lyon et al., 2011, Howes et al., 
2012b) and in CHR patients who subsequently develop a frank psychotic illness (Howes et al., 
2009b, Howes et al., 2011a, Howes et al., 2011b). Particularly high levels of DA in the striatum 
have been associated with positive symptom severity (such as hallucinations and delusions) as 
well as risk of relapse in psychosis (Kapur, 2003), consistent with evidence that drugs that 
increase DA release have the potential to induce or worsen psychosis (Lieberman et al., 1987, 
Howes et al., 2012a). Interestingly, a recent study found no significant difference in striatal DA 
levels between healthy controls and patients with treatment-resistant psychosis (i.e., patients 
who fail to show improvements in response to antipsychotic medications), indicating that other 
neurotransmitters systems may also contribute to symptom severity in psychosis (Demjaha et 
al., 2012). 
 
Increased DA levels in the striatum in patients with psychosis may be secondary to elevated 
glucocorticoid levels. Animal studies support this theory by showing an association between 
stress and DA release in the mesolimbic area of the brain (Schatzberg et al., 1985, Rouge-Pont 
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et al., 1993). A recent PET study by Mizrahi and colleagues (Mizrahi et al., 2012) aimed to clarify 
the relationship between stress and DA levels in psychosis: Twelve individuals at CHR for 
psychosis, 10 with FEP and 12 matched healthy controls underwent measures of cortisol as well 
as DA levels during a control task and a psychosocial stress task, the Montreal Imaging Stress 
Task (MIST) (Dedovic et al., 2005). Stress-induced DA increase in the striatum was significantly 
greater in both patients with FEP and individuals at CHR when compared to healthy controls. 
Consistent with this, changes in cortisol AUC showed significant group differences, with the 
psychotic group demonstrating the largest cortisol response to stress, and the CHR group 
midway between the controls and FEP group. Further, the percentage difference in cortisol 
between the control and stress tasks was significantly associated with PET indices of striatal DA, 
suggesting a direct relationship between stress induced DA release and salivary cortisol. 
 
A pathologic response to life stressors, in which a hyper-responsive dopaminergic system is 
thought to play a key role, is a potential etiologic factor in triggering psychotic symptoms and 
relapses in psychosis. In this context, it has been argued that treating high risk individuals with 
neuroleptics known to target DA activation in the brain may prevent or delay transition to 
psychosis (McGorry et al., 2002, McGlashan et al., 2006). However, this approach is highly 
controversial in light of the well-known side effects of antipsychotic medication and the 
comparable or even superior benefits of psychosocial interventions at the high risk stage 
(McGorry et al., 2009, Liu and Demjaha, 2013, Woods et al., 2013). 
It has been documented that social and environmental adversities, such as early traumatic 
events, social isolation, being an immigrant, or living in a big city may be important causes of 
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stress sensitization via a long-term dysregulation of DA systems (Howes and Murray, 2014). 
Such stress sensitization is evident in increased emotional reactivity to daily stress in adult life, 
which might result in further increases of DA levels, presumably constituting the link between 
stress and relapses in psychosis. All these risk factors have been included in a multi-
environmental social defeat model of psychosis risk (van Winkel et al., 2008), showing that 
social defeat stress leads to abnormalities in the dopaminergic neurotransmission. 
Investigating the link between abnormal DA release and adverse early life experiences, one 
study had screened 105 college students for childhood parental bonding, and five participants 
from the top and five from the bottom range were chosen to take part in a PET study 
(Pruessner et al., 2004). Individuals with low parental care showed increased midbrain DA 
release, and DA release was significantly correlated with cortisol levels in response to stress 
(Pruessner et al., 2004). These findings suggest that childhood adverse events are associated 
with an increase in mesolimbic DA levels in humans.  
In addition to DA abnormalities, researchers have described glutamatergic abnormalities in 
schizophrenia, which might also be modulated by stress exposure, including early trauma. 
Recent studies show associations between increased stress and glucocorticoid effects on 
glutamate transmission, including glutamate release, glutamate receptors and glutamate 
clearance and metabolism (Popoli et al., 2012). Glutamate has also been linked to treatment 
resistance in psychosis: Patients with treatment resistant illness did not show the elevated 
dopamine synthesis capacity in the striatum that is usually found in psychosis, but showed 
elevated glutamate levels in the anterior cortex compared to healthy controls (Demjaha et al., 
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2012, Demjaha et al., 2014). Thus, excess striatal DA synthesis is likely not the final common 
pathway in all psychotic individuals.  
Moreover, in some cases, elevated striatal DA levels might be driven by abnormalities in 
hippocampal glutamatergic neurotransmission. In a study of patients at CHR for psychosis, 
reduced hippocampal glutamate levels were associated with increased striatal DA uptake, 
which in turn was related to the severity of abnormal beliefs (Stone et al., 2010). This has led to 
the suggestion that an altered relationship between hippocampal glutamate and striatal DA 
systems may increase the risk for transition to psychosis (Stone et al., 2010). In an attempt to 
integrate these findings, it has been proposed that there are at least two possible explanations 
for the involvement of both dopamine and glutamate in psychosis (Howes et al., 2015); one, 
that these neurotransmitters are related to different subtypes of the disorder (i.e., glutamate 
abnormalities being a feature of treatment resistant psychosis), and two, that they contribute 
to different features of schizophrenia (i.e., dopamine abnormalities giving rise to the positive 
symptoms of psychosis whilst glutamatergic dysfunction underlies the negative and cognitive 
symptoms). 
 
 
8. Genetic vulnerability markers and psychosis 
8.1 Genetic factors and early adversity 
Psychosis is assumed to be a disorder with polygenic origins (Smoller and Finn, 2003, Giusti-
Rodriguez and Sullivan, 2013, Tesli et al., 2014) and shared genetic risk factors with bipolar 
disorder (Lichtenstein et al., 2009). Moreover, environmental risk and gene by environment 
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interactions are assumed to account for a substantial portion of the phenotypic variance. 
Recent studies focusing on gene-environment interactions between early life adversity and 
genetic vulnerability for psychosis lend support to this assumption (Vaillant and Schnurr, 1988, 
van Winkel et al., 2013). For example, for the brain-derived neurotrophic factor (BDNF) gene 
val66met, adult met carriers from the general population have greater increases in psychotic 
symptoms following stress, when compared to val/val carriers (Alemany et al., 2011). In 
individuals at GHR for affective disorder, Met carriers of the BDNF val66met also show an 
increased stress response to objectively stressful events compared to val/val carriers (Vinberg 
et al., 2009), and in a large sample of patients with psychotic disorders, met carriers with high 
levels of childhood trauma had the lowest BDNF mRNA levels. (Mondelli et al., 2011, Aas et al., 
2014b). These findings indicate that met carriers are more vulnerable to early trauma than 
val/val carriers. In fact, two recent studies in patients with psychosis show that met carriers 
exposed to childhood trauma have reduced cognitive function as well as a reduced volume of 
the dentate gyrus, a region in the hippocampus which is sensitive to stress and involved in 
neurogenesis (Aas et al., 2013, Aas et al., 2014b).  
Another risk gene related to increased stress reactivity is the serotonin transporter gene, 
specifically, the 5-HTTLPR functional polymorphism found in the promoter region of the 5-
HTT/SLC6A4. A large body of research demonstrates a relationship between variations in 5-
HTTLPR and the degree of the endocrine stress response (O'Hara and Hallmayer, 2007, Caspi et 
al., 2010). Interestingly, a higher cortisol response in s-allele carriers has been observed in 
healthy newborns (Mueller et al., 2010). Similarly, the serotonin transporter gene has been 
shown to modulate the effect of childhood trauma on cognitive function in patients with a 
psychotic illness, where patients carrying the ss genotype were more vulnerable to the negative 
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effect of trauma than ll and sl carriers (Aas et al., 2012a). Other commonly studied stress 
related genes are the FKBP5 gene (Klengel et al., 2013), and the glucocorticoid receptor gene, 
also called the NR3C1. Both genes are linked to long-term changes in the HPA axis following 
early stressful events.  
 
The studies described above provide further support for the neural-diathesis stress model by 
presenting evidence for the biological link between stress and DA activation and between 
genetic factors and stress vulnerability. However, it remains largely unexplored how genes are 
associated with DA release in response to stress (early adverse events or acute stress). A 
promising novel method for estimating the cumulative genetic risk of psychosis has been 
developed with a recent molecular validation of the psychosis continuum model (Bigdeli et al., 
2014, Tesli et al., 2014), providing a new tool to untangle the effects of genetic and 
environmental risk factors in psychosis. The polygenic risk score is calculated based on large 
genome-wide association studies of additional explained genetic variance previously classified 
as ‘missing’ (Iyegbe et al., 2014). An important next step is to investigate whether the 
polygenetic risk score for psychosis is linked to HPA axis activity and DA release in response to 
stressful events. 
 
8.2 Stress, glucocorticoids and epigenetic processes 
The term ‘Epigenetics’ refers to cellular factors and processes (e.g., DNA methylation, histone 
modification) that influence how our genes are expressed, without changing the actual DNA 
sequence genes. Recent research indicates that stressful events occurring in early life can cause 
long-term neurobiological changes and alterations in genes related to the HPA axis (Heim et al., 
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2000b, Heim et al., 2008, Heim et al., 2010, Klengel et al., 2013). For example, low maternal 
care in rodents has been linked to methylation of the promotor region of the glucocorticoid 
receptor (GR) gene and increased hormonal (corticosterone) responses to stress. (Weaver et 
al., 2004, Weaver, 2007, Champagne and Curley, 2009). A review examining the effects of early 
life stress on epigenetic modifications in humans concluded that DNA methylation may be 
critical to these processes (Champagne and Curley, 2009).  
 
More recently, it has been reported that childhood trauma is associated with increased 
glucocorticoid receptor (GR) gene promoter methylation and attenuated responses to the 
dexamethasone suppression test (Tyrka et al., 2012). Another study has additionally linked 
childhood trauma to altered methylation of the FKBP5 gene and long-term dysregulation of the 
stress hormone system in adult humans (Klengel et al., 2013), supporting the notion that stress 
may induce epigenetic effects on biological systems regulating the stress hormone release. 
 
Stress exposure in the perinatal period has also been related to a reduction in BDNF in the brain 
of adult rats (Riva, 2013), and it was proposed that epigenetic changes (i.e., an increase in 
methylation) caused by perinatal stress may contribute to reduced transcription of the BDNF 
gene and cognitive changes. It has also been postulated that different epigenetic changes relate 
to perinatal stress in animals in many genes, including those linked to schizophrenia and bipolar 
disorders (such as CACNA1C, DISC1, and COMT). It is therefore important to investigate the 
effect of stress on gene expression, not only on single genes, but across the genome to further 
understand how stress can alter gene expression in schizophrenia.  
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9. Stress, glucocorticoids and inflammatory processes 
Recent studies have implicated the immune system in the development of psychopathology 
with increased inflammation reported among individuals with depression (Leonard, 2001, 2007, 
Zunszain et al., 2011), schizophrenia, and bipolar disorder (Hope et al., 2009, Dieset et al., 
2012). Consistent with this, genome-wide association studies (GWAS) clearly indicate immune 
genes as susceptibility genes for schizophrenia, including the IL-IB gene and the major 
histocompatibility complex (Stefansson et al., 2009, Ripke et al., 2013). Furthermore, prenatal 
infections (e g., rubella, influenza, and toxoplasmosis) during fetal and early life have been 
associated with increased risk for severe psychiatric disorders in adulthood (Brown, 2006). 
  
Glucocorticoids, released in response to stressful events, are potent anti-inflammatory 
hormones in the body (Vinson, 2009); when stressors are acute and time-limited, such as fight-
or-flight stressors, there is an adaptive redistribution of cells as the natural immune system 
prepares for possible infection and/or injury (Segerstrom and Miller, 2004). However, as 
stressors become chronic, there are changes in the ability of the immune system to adapt. 
Acute stress versus chronic stress results in a shift from adaptive to maladaptive changes in the 
immune system. (For an in-depth discussion of chronic versus acute stress and inflammation, 
see the review paper by (Segerstrom and Miller, 2004). 
 
The HPA axis influences immunological responses via the effect of glucocorticoids on immune 
and inflammatory reactions, for instance on the cytokines interleukin (IL)-1 and IL-6. Both 
abnormal glucocorticoid function and increased inflammatory markers (i.e., cytokines and C-
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reactive protein) have been recently reported in patients with first-episode psychosis and in 
bipolar disorders (Potvin et al., 2008, Hope et al., 2009, Mondelli et al., 2010a, Mondelli et al., 
2011). Interestingly, IL-1beta and IL-6 have been indicated to play a central role in synaptic 
plasticity, neurogenesis and neuromodulation (Zunszain et al., 2011), suggesting that these 
cytokines may also influence cognitive function. A pilot study of patients with first-episode 
psychosis and healthy controls found a negative relationship between increased inflammation 
parameters (IL-8, and IL-6) and cognitive impairments (Aas, 2010), indicating that immune 
markers are related to cognitive function.  
 
Cognitive deficits are one of the core features in schizophrenia, with a performance that is on 
average one standard deviation lower than in controls across domains and apparent in first-
episode psychosis (Aas et al., 2014a). However, little is known regarding the mechanisms 
behind these impairments. As noted above (section 6), the observed associations between HPA 
axis function and neurocognitive impairments may reflect a direct effect of cortisol on the 
brain; here, we propose that at least some of this effect may be mediated by inflammatory 
processes.  
 
These above findings are consistent with the notion that inflammation is related to reduced 
BDNF levels (Smith et al., 2012, van Winkel et al., 2013); BDNF is important for growth and 
differentiation of neurons during brain development, as well as synaptic plasticity and 
maintenance of neurons in adult life (Lewin and Barde, 1996). As noted, exposure to 
psychosocial stressors such as childhood trauma is associated with reduction of BDNF RNA 
levels (Mondelli et al., 2011, Aas et al., 2014b). Indeed, at the cellular level, both acute and 
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chronically high levels of stress exposure are linked to atrophy of dendrites and suppression of 
neurogenesis (Sapolsky et al., 1986, Wolf, 2003), likely mediated by stress-based reductions in 
neurotrophic factors, including BDNF (Calabrese et al., 2009). It is possible that stressors in 
early life are related to long-term changes in the HPA axis, which in turn is associated with an 
up-regulation of the pro-inflammatory system. The pro-inflammatory system activation of 
microglia in the brain could potentially reduce BDNF levels, resulting in both cognitive deficits 
and brain abnormalities, such as reduced HV in schizophrenia. Further studies are needed to 
understand the role of inflammatory markers in the cognitive impairments that characterize 
severe mental disorders. Interestingly, drugs targeting the immune system, such as COX-2 
inhibitor (celecoxib) or COX-1/COX-2 inhibitor (aspirin), have recently been reported to 
significantly improve psychotic symptoms in patients with schizophrenia spectrum disorders, 
when used as adjunct therapy to antipsychotics (Muller et al., 2002, Akhondzadeh et al., 2007, 
Muller et al., 2010). 
 
A recent post-mortem study aiming to disentangle the relationship between stress and genes 
involved in inflammatory pathways showed that the brains of schizophrenia patients were 
more likely to be characterised by both high stress and high inflammatory markers compared to 
the brains of bipolar patients and controls (Fillman et al., 2014). There was also a trend for a 
higher than expected number of bipolar patients in this high stress/high inflammation category 
compared to controls. The study additionally provided evidence that inflammatory genes were 
more likely to be associated with schizophrenia whereas stress genes had a greater association 
with bipolar disorder. These findings suggest the importance of considering interactions 
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between stress signalling and neuroimmune pathways in the pathophysiological processes in 
psychosis. 
 
 
10. Neurodevelopmental processes and sex differences  
The idea that neurodevelopmental processes are implicated in the etiology of psychotic 
disorders is now generally accepted. Although neurodevelopmental models vary in terms of the 
developmental period (i.e., prenatal versus early postnatal or adolescence) and the 
mechanisms (i.e., prenatal versus early trauma or deviations in normal adolescent 
neuromaturation) that they emphasize, all share the assumption that the neuropathological 
process subserving psychosis begins prior to the clinical onset of the disorder (Rapoport et al., 
2012, Read et al., 2014, Waltereit et al., 2014). An overview of neurodevelopmental models of 
psychosis is beyond the scope of this paper, however, it is relevant to note that stress figures 
prominently in several models. 
 
The “traumagenic” neurodevelopmental model, for example, posits that the biological sequelae 
of early adversity sets the stage for the neuropathological process that is manifested as clinical 
psychosis later in life (Read et al., 2014). Others focus on prenatal insults and placental 
pathology, as well as mutations and rare genetic variants that can contribute to risk for later 
psychiatric disorder in a diagnostically nonspecific manner (Rapoport et al., 2012). Similarly, the 
genetic factors that influence developmental changes in synaptic plasticity have been 
hypothesized to play a key role for mental health outcomes (Waltereit et al., 2014). Other 
models have placed a greater emphasis on later developmental processes, including normative 
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increases in stress-sensitivity and HPA activation associated with adolescence (Holtzman et al., 
2013, Walker, 2008 #3729). Related to these post-pubertal processes, recent 
neurodevelopmental models have attempted to account for the well-established sex 
differences in premorbid and prodromal manifestations of risk for psychosis (Baldwin and 
Srivastava, 2015). 
It is possible that sex differences in brain development are at the core of the prominent sex 
differences in the clinical picture in psychosis and determine sex specific findings in HPA axis 
function and related brain and endocrine structures (see sections 2.6 and 3.5). Interestingly, sex 
differences in brain morphology in schizophrenia occur in areas that normally show sexual 
dimorphism, with some studies even pointing to a reversal of normal patterns of sexual 
differentiation in the brains of patients (Goldstein et al., 2002, Gur et al., 2004, Abel et al., 
2010). In other words, the same factors that control normal sexual dimorphisms may underlie 
the neuropathological processes leading to psychosis. 
Exposure to gonadal hormones during critical pre-, peri-, and postnatal stages is known to 
shape sex differences in brain morphology and HPA function. Stressful events and insults during 
these critical neurodevelopmental phases might thus have a different impact on 
neuropathologic processes in men and women (Goel et al., 2014). In particular, higher levels of 
estrogen are believed to constitute a protective effect at different stages of psychosis etiology 
in women and the lack this hormone constitutes a relative disadvantage in men. Estrogen 
effects range from sexual differentiation of the brain (Seeman, 1997, McEwen, 2002, Hafner, 
2003, Seeman, 2008, Abel et al., 2010), to shaping the HPA axis response to stress (Kirschbaum 
et al., 1999, Handa and Weiser, 2014) to exerting ameliorating effects on psychotic symptoms 
(Riecher-Rossler and Hafner, 1993, Hafner, 2003).  
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Subsequent sex specific influences on brain maturation and HPA axis regulation occur later in 
life (at the time of puberty and adulthood) and are believed to interact with the consequences 
of early neurodevelopmental insults. Such factors can cause further progression of brain 
abnormalities and are often associated with the onset of psychosis (Pantelis et al., 2003b, 
Phillips et al., 2006, McCormick and Mathews, 2007). For example, male compared to female 
patients frequently have a history of poorer premorbid adjustment, show lower levels of social 
development related to an earlier age of illness onset, exhibit more negative symptoms and 
have higher rates of substance use (Seeman, 2008, Ochoa et al., 2012). Furthermore, psychotic 
episodes themselves are considered “neurotoxic” (McGlashan and Johannessen, 1996) which 
could initiate additional harmful processes, especially in the brains of male patients.  
 
 
11. Discussion 
In this article, we have reviewed recent findings on stress and HPA axis functioning relevant to 
the neural diathesis-stress model of psychosis (Walker and Diforio, 1997, Walker et al., 2008). 
The review has provided a basis for validating elements of the original model and for extending 
the model to encompass more nuanced aspects of the potential role of stress and HPA axis 
function in the neuropathological processes involved in psychosis. In addition, the recent 
research findings have highlighted some of the complexities and challenges in this area of 
investigation. In this final chapter, we will summarize the insights from the investigation of HPA 
axis function in psychosis and CHR populations over the past decade and briefly explore the 
lessons learned from glucocorticoid induced psychosis for the causal relationship between 
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elevated glucocorticoid levels and psychotic symptoms, before presenting an extended neural 
diathesis stress model of schizophrenia and concluding with implications for future research 
and treatment strategies. 
 
11.1 Summary of HPA axis findings 
With regard to the elements of the original model, there is now additional evidence of elevated 
baseline cortisol in psychotic patients, especially for those who are not on antipsychotic 
medication. In fact, studies reported in the past decade have concluded, with few exceptions, 
that 1) atypical antipsychotics reduce basal cortisol levels (Cohrs et al., 2006) and 2) that the 
magnitude of cortisol reduction is associated with symptom severity reduction (Zhang et al., 
2005). Thus suppression of basal cortisol secretion may be a mechanism of antipsychotic action 
for some patients. Interestingly, it has recently been shown that patients with lower CAR show 
a less favourable response to antipsychotics (Mondelli et al., 2015), suggesting that CAR and 
basal cortisol levels are subserved by different mechanisms.  
In addition, there is now greater evidence that elevations in basal cortisol can be observed in 
CHR youth who, by definition, manifest attenuated positive symptoms. Moreover, as is the case 
with diagnosed psychotic patients, it appears that antipsychotic medication reduces cortisol 
levels in CHR subjects (Sugranyes et al., 2012). In contrast to findings from CHR samples, studies 
of subjects at GHR for psychosis were less likely to yield evidence of elevated cortisol. This 
would be expected, assuming that basal HPA hyperactivity is a risk factor for serious mental 
illness and that the representation of pre-psychotic individuals in GHR samples is lower than in 
CHR samples. 
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Cross sectional studies have not provided credible evidence for a relation between HPA axis 
changes and symptom severity. However, recent research indicates that higher cortisol is linked 
with a greater likelihood of conversion to psychosis, supporting our discussion in section 2.4, 
that longitudinal studies provide greater power for detecting effects and greater potential for 
inferring causation. 
In contrast to basal levels, a non-elevated or blunted response to acute stress has typically been 
reported in both established psychosis and in individuals at CHR for psychosis. The same 
conclusion was drawn in a recent review of research on stress and FEP (Borges et al., 2013). 
This pattern parallels findings of a blunted cortisol response to negative events and challenge 
tests in depressed patients, who are generally characterized by elevated baseline cortisol levels 
(Peeters et al., 2003). The dissociation of basal cortisol from stress-induced cortisol is not a 
novel finding. While one study reported an inverse association between basal and stress-
induced levels (Miller et al., 2013) and another investigation revealed a positive relation (Kidd 
et al., 2014), the majority of reports indicate no significant relationship in healthy children 
(Dietz et al., 2013) and adults (Miller et al., 2011, Tomiyama et al., 2012). Similarly basal cortisol 
has been found to be unrelated to ACTH-induced cortisol responses (Bollaert et al., 2003, de 
Jong et al., 2007).  
In addition to the absence of an augmented cortisol response to acute challenge, the 
accumulating literature suggests that a blunted CAR characterizes diagnosed psychotic patients, 
with conflicting reports in CHR samples (Berger et al., 2016). While the latter could be explained 
by the heterogeneity of the clinical picture in CHR populations and the relatively small numbers 
of converters to psychosis (Fusar-Poli et al., 2012a), measuring the CAR is challenging, and the 
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determinants are not yet fully understood (Stalder et al., 2016). It appears that the CAR is 
independent of daytime basal cortisol levels (Fries et al., 2009; Wilhelm et al., 2007; (Laceulle et 
al., 2015) and of stress-induced cortisol (Kidd et al., 2014, Laceulle et al., 2015). Although this 
independence of various cortisol indices is not explicable by the law of initial value (see 2.8.3), 
both elevated basal cortisol levels and attenuated cortisol levels to stress and awakening are 
likely the consequence of a general dysregulation of the HPA axis. In support of this notion, it 
has been proposed that attenuated cortisol responses are the consequence of a prolonged 
period of hyperactivity of the hypothalamic-pituitary-adrenal axis due to chronic stress (Heim et 
al., 2000a, Fries et al., 2005). While the experience of psychosis could have constituted such a 
chronic stressor, the experience for CHR individuals will likely have been less chronic. It can be 
assumed that the underlying mechanisms determining elevated cortisol levels at baseline and 
attenuated responses to stimulation differ and that their interplay is complex. In the context of 
hypocortisolism, dysregulations on several levels of the HPA axis have been discussed, such as 
reduced adrenocortical sensitivity to ACTH (Schmidt-Reinwald et al., 1999, Rohleder et al., 
2003, Meinlschmidt and Heim, 2005), down-regulation of CRF receptors in the pituitary causing 
blunted ACTH responses, increased feedback sensitivity of the HPA axis, and morphological 
changes (Heim et al., 2000a). Furthermore, findings of a missing CAR and cortisol response to 
psychosocial stress in patients with hippocampal damage (in the context of a normal diurnal 
patters) suggest that hippocampal integrity is crucial for HPA axis responsiveness but not for 
basal cortisol (Buchanan et al., 2004, Wolf et al., 2005, Buchanan et al., 2009). 
A lesson that can be learned from the incongruent findings is that differences in various indices 
of HPA axis activation must be taken into consideration and incorporated into models when 
conceptualizing the role of stress and the HPA axis in the etiology of psychosis. Furthermore, it 
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is clear that the origin of the HPA axis dysregulation cannot be determined through studies 
using salivary cortisol alone, since many levels and secretagogues of this complex system can be 
involved (Binder and Holsboer, 2012). Additional research examining the relationship between 
various HPA axis measures and related brain morphological, receptor level, molecular, genetic 
and epigenetic changes may provide a better understanding of the complex mechanisms 
involved in hyper- and hypo-activation and help to explain the inconsistent findings.  
 
11.2 What can we learn from glucocorticoid induced psychosis? 
Before turning to a discussion of revisions to the neural diathesis-stress model, it is relevant to 
first revisit the possibility that the abnormalities of HPA function found to be associated with 
psychosis are primarily or solely illness-induced; in other words, that elevated cortisol levels are 
a consequence of the stress associated with the prodromal and clinical symptoms of psychosis. 
While this is possible, there is now more extensive evidence from several areas of inquiry that 
elevated cortisol levels do increase the risk of psychosis. The accumulating body of literature on 
secondary effects of glucocorticoid treatment of illnesses (e g., allergic, inflammatory or auto-
immune disorders) (Dubovsky et al., 2012, Ross and Cetas, 2012, Judd et al., 2014, West and 
Kenedi, 2014) and research on neuropsychiatric complications associated with 
hypercortisolemia in Cushing’s disease (Pivonello et al., 2015) support this view. The incidence 
of severe psychiatric symptoms following treatment with corticosteroids is estimated to be 
about 6%, and the incidence of any symptoms about 20% (Dubovsky et al., 2012, Ross and 
Cetas, 2012). However, these figures are likely to be underestimates as the majority of studies 
in this field focus on physical side effects, and do not conduct systematic evaluations of the 
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range of psychiatric symptoms (Dubovsky et al., 2012). Documented steroid-induced symptoms 
include mania, sleeplessness, anxiety, distractibility, depersonalization, cognitive deficits, and 
psychosis (Dubovsky et al., 2012). “Steroid-induced psychoses” can range from mild 
disorientation to frank psychosis, and the risk increases in a dose-response manner, with 
symptoms usually remitting within several weeks following cessation of steroid treatment (Ross 
and Cetas, 2012). Similarly, common psychiatric symptoms associated with hypercortisolemia in 
untreated Cushing’s syndrome, include depression, mania, anxiety, cognitive deficits and 
psychosis (Dubovsky et al., 2012, Pivonello et al., 2015). Again, symptoms usually remit after 
effective treatment of hypercortisolism, and the decline in salivary cortisol in response to 
treatment of Cushing’s is associated with the resolution of psychosis (Myhill et al., 2008). 
Further, the psychotic symptoms associated with both steroid administration and Cushing’s 
disease are reduced by antipsychotic medication. Finally, one recent study found that men 
were more prone to develop psychosis like features such as mania, delirium, confusion and 
disorientation when exposed to CG treatment compared to women. In contrast, women in this 
study were more likely to develop depression than men (Fardet et al., 2012). This finding is 
consistent with the notion that the higher incidence of psychosis and relatively poor outcome in 
men is a consequence of a higher vulnerability to stress resulting in more severe HPA axis 
dysregulation.  
In addition to providing support for the assumption that heightened cortisol increases risk for 
psychosis, the above findings also illustrate 1) the nonspecific nature of the effects and 2) the 
importance of individual differences. Increased cortisol levels are associated with a range of 
mood, cognitive, and psychotic symptoms, and treatment aimed at reducing elevated cortisol 
results in significant remission in all symptom domains. Thus adverse effects of stress and 
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heightened HPA activity are not specific to psychosis. The above findings on steroid treatment 
and Cushing’s disease also clearly illustrate the individual differences in vulnerability to the 
adverse effects of elevated cortisol. Whether induced by stress, maturational changes, disease 
processes (e g., Cushing’s), or corticosteroid treatment, individuals vary in their responses to 
elevated glucocorticoids. Only a subgroup develop a psychiatric syndrome and, of these, only a 
subgroup manifest psychosis. Of course, it is now widely accepted that the aetiology of serious 
mental disorders is complex, and that no single risk factor or neuropathological process will 
account for all cases of any diagnostic entity. This certainly holds for HPA abnormalities in 
psychosis.  
 
11.3 An extended neural-diathesis stress model 
Based on the complexity of findings reviewed in this paper, revisions and elaborations on the 
neural diathesis stress model are presented below. The extended model is not intended to be 
comprehensive, in that not all potential processes and pathways can be incorporated. It is, 
however, configured to accommodate the growing trends in the empirical literature on stress, 
HPA function, and psychosis. It should also be emphasized that the model cannot account for 
all cases of psychosis, but instead is posited to account for the specific etiologic pathway, which 
is characterised by glucocorticoid sensitivity. Finally, the processes included in the model are 
not assumed to be specific to psychosis; similar processes may be involved in the aetiology of 
other psychiatric disorders. The nature of the disorder is assumed to be determined by a 
cascade of interactions of these processes with pre-existing and progressive vulnerabilities. 
In Figure 1 below, an updated neural diathesis-stress model is illustrated. 
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- - - - - - - - - - - - 
Insert Figure 1 
- - - - - - - - - - - - 
 
 
As shown in Figure 1, beginning in the first column on the left, we hypothesize that, 
commencing early in life (as early as conception), a range of genetic and environmental factors 
act, in isolation or in concert, to increase vulnerability for psychosis by setting into motion a 
vicious cycle of progressive degenerative processes that derail neuromaturation and increase 
psychosis risk. Genetic predisposition includes inherited risk alleles and genetic mutations. In 
some cases, genetic predisposition may include genes that are relevant to HPA axis function 
(e.g., FKBP5 and BDNF). Early life adversity factors include, but are not limited to, pre-, peri- and 
post-natal stress and insults, childhood trauma, poor parental bonding; 
Environmental/psychological stressors include stressful life events, low socio-economic status, 
ethnic minority status, city living, substance use; Resilience factors include social support, self-
esteem, coping skills, and antipsychotic medication.  
As illustrated in the second column, early or later environmental insults contribute to stress 
system dysregulations (particularly of the HPA axis) and brain degenerative processes in regions 
that are involved in modulating HPA axis function (e.g. the hippocampus). Initially minor or 
subtle deviations from normal neurodevelopment build up to render these physiological 
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response systems increasingly more susceptible to future stressors. Once homeostasis of the 
system is disrupted, neurotransmitter, inflammatory and cognitive changes further propagate 
psychosis-relevant developmental deviations and may lead to epigenetic changes.  
Disturbance in HPA axis function that precedes the onset of psychosis (and can act as a trigger 
for the expression of psychotic symptoms) initially occurs in parallel with the abnormal 
trajectory of neurodevelopment that lays the foundations for the disorder. However, once the 
HPA axis reaches the point of ‘abnormal function’, this system interacts with the ongoing 
neurodevelopmental processes to further propagate psychosis-relevant changes in brain 
structure and function.  
The most dramatic neurodevelopmental and HPA axis changes occur in adolescence, which is 
the time when prodromal and frank psychotic symptoms most frequently occur for the first 
time. The onset of puberty then amplifies the neuropathological process because the brain 
undergoes significant restructuring, and basal activity of the HPA axis increases. Earlier adverse 
effects of trauma and stress on HPA axis function may then be augmented during the course of 
post-pubertal maturation by the normative increase in cortisol secretion and the greater 
divergence of brain structures from the norm among those with greater vulnerability for 
psychosis, thus rendering the system more susceptible to environmental stressors. A greater 
magnitude of the HPA axis response during adolescence, may cause environmental stressors, 
such as substance misuse, adverse experiences and negative life events, to tip the axis into a 
state of hyperactivity and/or dysregulation characterized by elevated basal cortisol levels, 
decreased glucocorticoid receptor expression, a blunted CAR, and a dampened cortisol 
response to stress with consequences for pituitary volume enlargement and hippocampal 
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volume decline. The manifestation of the HPA axis abnormality is likely dependent on the 
extent of prior (pre-pubertal) dysregulation and effect modifiers such as sex, coping strategies, 
and pharmacological treatment.  
It is this state of HPA axis abnormality that enhances the ongoing process of 
neurodevelopmental deviance, initially triggering subthreshold symptoms and eventually 
resulting in the expression of full psychotic symptoms. There are several ways by which the HPA 
axis can bring about these changes: (1) HPA axis hyperactivity leads to an increase in cortisol, 
which then has a damaging effect on specific brain regions, which express high levels of 
glucocorticoid receptors (i.e., the hippocampus and medial prefrontal cortex (mPFC), thereby 
leading to impairments in the cognitive abilities attributed to these regions (i.e., memory and 
executive function), (2) as described previously, the increase in glucocorticoids has the effect of 
increasing dopamine levels, which in turn gives rise to more prominent psychotic symptoms 
(perhaps by aberrant attribution of salience to benign stimuli), (3) glucocorticoids, being steroid 
hormones, lead to epigenetic modifications in key genes which influence brain development 
(e.g., BDNF) and stress responsivity; thus, further enhancing the pattern of 
neurodevelopmental abnormality and also influencing the ability of the HPA axis to respond to 
subsequent stress (perhaps rendering the latter less response to further stimulation including 
awakening), (4) HPA axis dysfunction leads to glutamatergic abnormalities which may promote 
the expression of negative symptoms and enhance cognitive deficits, and (5) cross-talk between 
the HPA axis and the inflammatory system leads to an increase in peripheral inflammation and 
subsequently neuroinflammation, the latter having further damaging effects on the still 
developing brain.  
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Early stages of psychosis progression manifest through poor functioning and behavioral 
abnormalities and later through psychotic antecedents during childhood. The experience of 
prodromal or psychotic symptoms can cause significant psychological and environmental 
distress and has the potential to aggravate the cascade of neurobiological disturbances.  
Resilience factors such as social support and psychosocial interventions to increase self-esteem 
and promote efficient stress management strategies might dampen the vigor of the stress-
vulnerability cycle. Following the first psychotic episode, effective treatment with antipsychotic 
agents may normalize basal cortisol; however, other disturbances in HPA activity (i.e., 
attenuated response to psychosocial stress or awakening) may persist. In addition, while 
antipsychotic treatments may reduce dopamine activity, thereby ameliorating psychotic 
symptoms, other features (e.g., glutamatergic dysfunction, cognitive deficits, neuroanatomical 
abnormalities, and inflammation) may not improve or may even worsen over time. 
 
11.4 Implications for future research 
Compared to the original model formulated almost two decades ago, the extended neural 
diathesis stress model of schizophrenia includes new and refined definitions of markers and 
mediators of stress vulnerability in psychosis, which have the potential to guide future research 
endeavors in the field of stress and psychosis and delineate the starting points for alternative 
treatment strategies. Many of the suggested future lines of research and treatment will be 
relevant across clinical domains. 
One important avenue of future research suggested by the presented findings is the 
investigation of associations between various markers of HPA axis activity (i.e. basal cortisol, 
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cortisol awakening response, cortisol response to stress and various challenge tests) employing 
intra-individual and longitudinal designs. Such research is expected to provide a better 
understanding of the relevance and interplay of these various markers, id in the explanation of 
hitherto conflicting findings, and improve our understanding of the specific profile of HPA axis 
abnormalities in psychosis. 
This research may furthermore result in recommendations for the most appropriate measures 
of HPA axis function and consensus guidelines for best practice assessment of these markers. 
Such consensus guidelines have recently been published for the CAR (Stalder et al., 2016). This 
paper also showcases the many complexities in the assessment of just one of the various 
measures of HPA axis function. In this context the best possible control for common 
confounding factors, including such measures as menstrual cycle phase in women, the time of 
awakening and circadian rhythm, should be aspired. 
As outlined in section 2.2, there is evidence for a complex interplay between the HPA axis and 
the SAM system. A closer inspection of various physiological stress responses and their 
interaction in the field of psychosis will likely provide a more complete understanding of both 
short- and long-term stress effects on illness onset and progression. Such research might also 
resolve the frequently observed discrepancy between perceived stress and physiological stress 
responses. 
Animal studies and human imaging studies can provide insight into gene expression, brain 
substrates, molecular and receptor related changes associated with stress experiences, HPA 
axis and clinical outcome measures. Ideally, various additional measures related to stress 
vulnerability and psychosis progression (i.e. brain structure and function, dopamine, glutamate, 
 
 
78 
immune function, genetic factors, sex differences, cognition) would be assessed within the 
same patient study. While this might be challenging due to the often small patient populations 
at single sites, especially in clinical high risk populations, efforts should be made for researchers 
to link data acquisition and analysis in populations with comparable intake criteria and 
assessment protocols, thus ensuring sufficient sample sizes allowing for multifactorial analyses. 
One of the most crucial and challenging research questions is how findings on stress and 
related neurobiological changes can contribute to the prevention of psychosis. Accumulating 
research on clinical high-risk states has emerged in recent years, and researchers need to 
continue their efforts to identify common risk and protective factors for conversion to 
psychosis. While the identification of individuals who are more proximal to psychosis promises 
the most accurate identification of risk and protective factors and allows the identification of 
targeted intervention strategies, researchers must also focus on containing the effects of 
genetic predisposition and early life adversity and their detrimental effects on the stress 
vulnerability cycle and related progressively increasing psychosis risk. Here, there is a critical 
need for large-scale population-based observation and intervention studies. 
Such longitudinal studies are needed to draw inferences about stress experiences, HPA axis 
function and other measures of interest on neuromaturational processes and symptomatic 
outcome over time. They furthermore will allow the identification of different illness 
trajectories in the presence of various risk and protective factors. 
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11.5 Implications for treatment strategies 
The prevention of onset or exacerbation of psychosis on the basis of knowledge on 
neurobiological, environmental, psychological and cognitive determinants and consequences of 
stress is a promising prospect in the face of the often debilitating consequences of psychotic 
illness and the serious side effects of antipsychotic medication. Especially the normalization of 
HPA axis function is increasingly viewed as an important therapeutic approach for psychosis 
and high-risk populations (Garner et al., 2009). As an example, Wolkowitz and colleagues have 
proposed that elevated GC activity is associated with a down-regulation of GR receptors in the 
hippocampus, leading to GC resistance, followed by a cascade of events leading to further 
cellular damage and pathological outcomes (Wolkowitz et al., 2009). The authors propose 
various treatment strategies to upregulate GR function and correct the metabolic 
consequences of GR function deficits, including antidepressant medication with certain 
selective serotonin re-uptake inhibitors (SSRIs), corticotrophic releasining hormone (CRH) 
antagonists, stress reduction and behavioural interventions, environmental enrichment and 
exercise. Although anti-glucocorticoid agents have been proven effective for the treatment of 
some patients with depression (Reus and Wolkowitz, 2001) and a recent review reports some 
favorable effects of the glucocorticoid receptor antagonist mifepristone on short term positive 
symptom outcome in psychosis (Garner et al., 2016), there is currently insufficient evidence to 
conclude that antiglucocorticoid drugs constitute effective treatments for psychosis or even 
have the potential to prevent the onset of the illness in CHR subjects. Together with some 
serious side effects of antiglucocorticoid drugs (Reus and Wolkowitz, 2001), a general 
recommendation for their application seems premature, and additional large-scale studies are 
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needed to test the efficacy of pharmacological interventions at different levels of the HPA axis 
(Garner et al., 2009, Garner et al., 2016).  
In the meantime, the use of non-pharmacological approaches to reduce stress and increase 
resiliency towards stress should be the preferred choice of treatment in the early stages of 
psychosis, especially in high-risk populations. A recent review on psychosocial treatments for 
psychosis attests to the substantial progress in the use of psychosocial interventions and their 
effectiveness to reduce stress and improve symptoms and functioning (Mueser et al., 2013). 
Psychosocial interventions targeting symptoms and psychosocial functioning include cognitive 
behavioural therapy, family psychoeducation, illness self-management training and social skills-
training. Although these interventions are evidence based and have shown to improve a broad 
range of outcomes, the authors note a lack of accessibility to such interventions in mental 
health settings. Furthermore, intervention studies targeting stress reduction in psychosis often 
lack a proper assessment of stress and HPA axis function. 
A recently developed program for high school children has proven effective in averting high 
stress levels and elevated cortisol levels and thus prevent the onset of mental illness. In her de-
stress for success program, Lupien and colleagues developed a school based education program 
to alleviate the stress of transition to high school. The authors observed that students whose 
cortisol levels decreased in response to the intervention also had a significantly decreased risk 
for depressive symptomatology three months post intervention (Lupien et al., 2013). 
Specifically designed stress management programs for psychosis have furthermore shown a 
reduction in hospital admission in the year following the intervention (Norman et al., 2002). 
There is a critical need for further intervention studies investigating the effectiveness of 
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alternative pharmacological and psychosocial interventions to alleviate subjective and 
physiological stress response, with the ultimate goal to reduce the risk for psychosis onset and 
progression. Here, knowledge about inter-individual differences in stress vulnerability and 
psychosis risk can lead to the development of targeted interventions and assessment of their 
effectiveness.  
 
11.6 Conclusions 
In conclusion, the present paper provides a thorough review of the recent evidence on HPA axis 
dysregulation among individuals with and at-risk for psychotic disorders, taking into 
consideration how abnormalities within the HPA axis might interact with other neurobiological 
systems to give rise to psychosis. Based on the complexity of these findings, we have proposed 
an extension of the original neural diathesis stress model, and have provided suggestions for 
further research in the field. We hope that this review sensitizes researchers towards the 
multiple methodological challenges that can obscure the interpretation of findings and 
stimulates the design of guidelines for investigation of HPA axis activity in the context of 
psychosis. This is expected to ultimately advance our understanding of stress and stress-system 
related mechanisms for the etiology of psychotic disorders and may help to identify successful 
treatments to prevent psychosis onset and progression of symptoms. 
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Figure Captions 
 
Table 1: Summary of cortisol abnormalities among individuals with established psychosis and 
at-risk groups relative to healthy controls. Upward arrow indicates increased cortisol in 
patient/high-risk group relative to healthy controls; Downward arrow indicates decreased 
cortisol levels in patient/high-risk group relative to healthy controls; ‒ no difference between 
patient/high-risk group and healthy controls; 2-DG: 2-deoxy-D-glucose.  
 
Figure 1. The extended neural diathesis-stress model of schizophrenia: (A) Rightward arrows 
indicate the contribution of vulnerability factors to neurodevelopmental alterations that 
predispose the individual to maladaptive responses to later stressors, eventually increasing the 
risk for psychosis onset. Leftward arrows from psychosis progression illustrate the potential for 
prodromal/psychotic symptoms to both aggravate the cascade of neurobiological disturbances 
and further enhance vulnerability. (B) Downwards arrows indicate the progression of psychosis 
from early antecedents to chronic illness. (C) Curved arrows depict the bidirectional cause and 
effect relationship between HPA axis alterations and degenerative brain processes. (D) Two-
way arrows emphasize the complex interactions between the HPA axis and other biological 
systems. (E) Dashed arrows demonstrate the downstream effects of brain degenerative 
processes. HPA: hypothalamus-pituitary-adrenal axis; CHR: clinical high risk. 
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